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Drug-induced acute liver injury (DILI) is a major clinical problem 
arising from both diseases and therapeutic misadventures. This issue not only 
translates into significant morbidities and mortalities worldwide, but also 
causes the repercussions of drug removal from market and socio-economic 
burden. Management of DILI is often limited to cessation of drug use and 
supportive therapy, as there are no therapeutically proven natural 
hepatoprotective agents. Current treatment using N-acetylcysteine (NAC) has 
narrow therapeutic window and only effective when administered at a very 
early stage of the injury. To address this unmet need, we are interested in 
exploring two potential natural hepatoprotective or hepatoregenerative agents, 
exosomes and alpha-tocotrienol (-T3) in the acute liver injury model. 
Hitherto mesenchymal stem cell (MSC) and the conditioned medium (MSC-
CM) was shown to be effective in treating various organ failure, including 
liver. Later, MSC-CM derived exosomes was identified to play a vital 
functional role in tissue repair. Nevertheless, the hepatoprotective or 
hepatoregenerative effect of exosomes has never been demonstrated. On the 
other hand, Vitamin E has been well-known for its antioxidant property with 
-tocopherol (-TP) being the most active form. However, recent research 
showed that tocotrienols (or T3, another subtype of Vitamin E) analogs exert 
better functions in health and disease distinct from -TP, especially -T3 in 
overcoming neuronal injury and ischemic perfusion injury. However, the 
hepatoprotective effect of specific analogs of T3 has yet to be identified. 
Therefore, our overarching aim was to determine if MSC-CM derived 
x 
 
exosomes and isoforms of T3 are hepatoregenerative and/or hepatoprotective 
in overcoming DILI.  
 The effect of exosomes (Chapter 3) was investigated in vivo followed 
by in vitro whereas the effect of T3 analogs (Chapter 4) was investigated only 
in vitro. Exosomes were introduced concurrently with CCl4 into a mouse 
model through different route of administration. Biochemical analysis was 
performed based on the blood and liver tissues. Subsequently the exosomes/T3 
analogs were evaluated in APAP and H2O2-toxicants in vitro models. Cell 
viability was measured and biomarkers indicative of regenerative and 
oxidative biochemical responses were determined to probe into the mechanism 
of any hepatoprotective or hepatoregenerative activity observed. 
 In contrast to PBS-treated mice, CCl4 injury in mice was attenuated by 
concurrent-treatment exosomes, and characterized by an increase in 
hepatocyte proliferation as demonstrated with PCNA elevation. Significantly 
higher cell viability was demonstrated in the exosomes-treated group as 
compared to the non exosomes-treated group in both APAP and H2O2 injury 
models. The higher survival rate was associated with upregulation of the 
priming phase genes during liver regeneration which subsequently led to 
higher expression of proliferation proteins and prevention of apoptosis in the 
exosomes-treated group. In contrast to that, -T3 but not other T3 analogs was 
found to be effective in preventing both toxicants induced injuries. -T3 
preserved cell viability by acting against the build-up of ROS and its 
downstream pathway which inhibited the injury and initiation of apoptosis. 
Finally, the combination therapy of exosomes and -T3 demonstrated better 
restoration of viability compared to respective single treatment, acting in 
xi 
 
concert with each other complementing the protection against DILI (Chapter 
5). 
In summary, these results suggest that MSC-derived exosomes can 
elicit hepatoprotective and hepatoregenerative effects against toxicants-
induced injury mainly through activation of proliferative and regenerative 
responses while -T3 prevented the hepatocytes injuries caused by oxidative 
stress during DILI through its potent antioxidant properties. These two agents 
participate distinctively in different aspects of hepatoprotection and 
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1.1 LIVER INJURY AND ITS PATTERN 
 
Liver injury is one of the leading causes of death worldwide, and is the 
only major cause of death still increasing year-on-year [1], accounting for 
more than 330,000 deaths in United States in 2011 [2]. Histopathologically, 
liver injury can be distinguished into hepatocellular, cholestatic, and mixed 
injury by measuring the alanine aminotransferase (ALT), alkaline phosphatase 
(ALP) and total bilirubin (TB) level in the liver function test (LFT). Among 
the three types of liver injury, hepatocellular-predominant injury leads to more 
ominous progression in acute liver failure. Clinically, hepatocellular injury is 
characterized by disproportionate elevation of ALT compared to TB and ALP 
level, with the degree of elevation being more than three times the upper limit 
of normal (ULN) and with a ratio of ALT/ALP (referred to as R value) more 
than five [3]. Hepatocellular injury reflects damage at the hepatic parenchyma 
which leads to apoptosis and cytolytic necrosis [4]. Cholestatic injury on the 
other hand involves increase in ALP more than two times ULN with R values 
less than two, while mixed liver injury is characterized by equivalents of 
elevations in ALT and ALP which is more than two times ULN, and R values 
in between two and five [3]. The later injury is often mixed with prominent 






1.2 CLINICAL OUTCOMES OF DRUG-INDUCED LIVER INJURY  
 
Liver is one of the few organs in the body that has the ability to 
regenerate from the replication of mature functioning liver cells, without 
recruitment of liver stem cells [5, 6]. However when liver injuries progress 
into a state of functional impairment, it can lead impede self-renewal and also 
cause severe consequences that include acute liver failure or death [3]. Today, 
acute liver injury is a major clinical problem arising from many causes 
including diseases and therapeutic misadventures, with approximately 2000 
cases each year and 80% mortality. In United States, virally-induced disease 
predominated in early 90s but has substantially declined in the past few years, 
with most acute injury cases now arising from drug induced-liver injury (DILI) 
[7]. 
In the United States, DILI accounts for more than 50% of acute liver 
failure and is the prominent cause of liver transplantation [8]. More than 1,000 
therapeutic agents and herbal remedies are believed to be hepatotoxic. Among 
which, the drug most often implicated in such cases is acetaminophen (APAP), 
also known as paracetamol, which represents 75% of DILI cases and 42% of 
U.S acute liver failure cases [9]. This injury is often followed by rapidly 
progressive multi-organ failure, exhibiting greater severity of illness than seen 
in other causes of liver failure [10]. Nevertheless, other drugs which cause 
DILI may also lead to patient morbidity and mortality. Majority of the adverse 
DILI events are unpredictable, arising from either immune-mediated 
hypersensitivity reactions or of idiosyncratic origins [11]. Idiosyncratic 
reactions normally occur in 5-90 days after the causative medication was last 
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taken [12] and for this reason, such toxicities are not clearly associated with 
the drug administration as the causative agent during clinical testing. They are 
usually not noted until a drug has been on the market and has gained broad 
exposure. As a consequence, DILI is currently the most common reason for 






1.3 MECHANISM OF LIVER INJURY 
 
Compared to other organs, liver is particularly susceptible to drug-
induced injury due to its innate role in the clearance, biotransformation and 
excretion of medications and other xenobiotics. Approximately 75% of hepatic 
blood comes directly from the gastrointestinal viscera and spleen via the portal 
vein, inadvertently exposing the liver to higher concentrations of drugs and 
xenobiotics [14, 15]. While the abundance of the drug-metabolizing enzymes 
within the liver generally detoxify xenobiotics, the same processes may 
occasionally increase the toxicity of these xenobiotics through mechanisms as 
described in section 1.3.1 [16].  
Metabolism comprises of two broad categories, namely phase I and 
phase II metabolism. Generally, phase I reactions increase the drug polarity 
via functionalization reactions such as oxidation, reduction and hydrolysis to 
facilitate their elimination directly or upon further conjugation with other 
hydrophilic moiety during phase II metabolism. Hence, phase II reactions 
conjugate xenobiotics with hydrophilic moieties such as glutathione (GSH), 
glucuronic acid, sulfate, or amino acids [16]. While overall aim of drug 
metabolism is to detoxify the drug by forming them into a more water-soluble 
and easily excreted metabolite, it can also result in either bioactivation or 






1.3.1 General drug-induced liver injury mechanism 
The general mechanism of DILI as understood today can involve two 
distinct pathways - direct hepatotoxicity or indirect adverse immune reactions. 
In most occasions, direct hepatotoxicity refers to the injury in hepatocytes 
initiated by the bioactivation of drugs to chemically reactive metabolites. 
Reactive metabolites can bind covalently with cellular macromolecules such 
as nucleic acids, proteins and lipids, leading to DNA damage, protein 
dysfunction, lipid peroxidation (LPO), and oxidative stress [17, 18]. These 
events subsequently lead to disruption of intracellular calcium homeostasis, 
mitochondria dysfunction and loss of energy production, eventually initiate 
cascade of caspases which results in apoptosis or necrosis [14]. These direct 
hepatotoxicity mediated injury mechanisms provide key indicators for injury 
monitoring and also for devising management strategies. Therefore, these will 
be discussed in detail in the following section using APAP as a classical 
example. Besides binding of cellular macromolecules and causing direct 
functional loss, toxic metabolites could modify cellular targets to yield new 
epitopes and incite immunologic reactions leading to hypersensitivities. This 
process can also produce cytotoxic mediators, such as reactive oxygen species 
(ROS) and pro-inﬂammatory mediators (such as cytokines and chemokines) 
for the progression of the injury. Importantly, the two orthogonal pathways 
may not be mutually exclusive. Both could be at work concurrently, or 
manifested to different extent within the same injury event. For this reason, 
investigative work to understand the mechanism of toxicity for specific drugs 




1.3.2 APAP-induced liver injury mechanism 
Due to the limitation that very few drugs which cause liver injury in 
humans can be studied in animals, there is a lack of mechanistic understanding 
of how drugs cause liver injury until the advent of APAP. APAP is a classic 
hepatotoxicant and its complex role of different mechanisms in DILI has been 
studied extensively. Therefore, the role of signaling pathways involved in 
DILI can be examined based on the signaling pathways that are important in 
mediating APAP-induced liver injury. APAP at its recommended doses is 
generally safe, but its intrinsic toxicity at higher doses represents the most 
vital cause of acute liver failure.  
 
1.3.2.1 NAPQI formation 
APAP is predominantly metabolized by direct conjugation with sulfate 
or glucuronic acid through sulfotransferases or glucoronyltransferases 
respectively and excreted into bile [19]. The remaining minor part of APAP is 
metabolized by a cytochrome P450 into N-acetyl-p-benzoquinoneimine 
(NAPQI) (Figure 1). NAPQI is a major reactive metabolite serving as an 
oxidant which is responsible for cytotoxicity and hepatotoxicity [20]. NAPQI 
both arylates (covalent binding) and oxidizes (S-thiolation) nonprotein and 
protein thiols. Although arylation may occur to a lesser extent than oxidation, 
it appears to be a more damaging event [19]. Detoxification of APAP at 
therapeutic doses involves the rapid quenching of NAPQI by a spontaneous 
conjugation reaction with GSH. However a toxic (over) dose will result in 
profound depletion of GSH [21], and this process marks the initiation of 









Figure 1 Schematic representation depicting the role of metabolism in 




1.3.2.2 NAPQI and protein binding 
When the liver GSH levels were exhausted, the unquenched reactive 
metabolite can covalently bind to cellular proteins including plasma 
membrane and mitochondria. Glutathione peroxidase (Gpx) and adenosine 
triphosphate (ATP) synthase -subunit were among the targets affected. It was 
reported that the APAP administration reduced 60% of Gpx activity [23] and 
modified ATP synthase -subunit which caused malfunction of ATP synthase 
and depletion in ATP [24]. Apart from that, the decrease in cellular ATP 
compromised the activity of the ATP-dependent calcium pump of the plasma 
membrane, and disrupted intracellular Ca
2+ 
homeostasis [25]. As a 
consequence, several calcium-dependent degradative enzymes will be 
activated, including endonucleases that cleave DNA [19]. Apart from NAPQI, 
these reactions also apply to the reactive metabolites formed from other 
hepatotoxicants such as carbon tetrachloride (CCl4), allyl alcohol, and 
bromobenzene. Overall, the binding of reactive metabolites to mitochondrial 
proteins is a critical initiating event which triggers the mitochondrial oxidant 





1.3.2.3 Mitochondrial superoxide and peroxynitrite formation 
On the other hand, the cycling of oxidized and reduced forms of 
toxicants such as NAPQI generates reactive superoxide radical anions (O2
  ). 
Due to the inhibition of Gpx activity, the formation of superoxide in the 
mitochondria will thus increase and subsequently lead to the formation of 
hydrogen peroxide (H2O2) and hydroxyl radicals (
OH) [18]. Besides that, the 
superoxide can also react with nitric oxide (NO) spontaneously to form 
peroxynitrite (ONOO
  
), a potent oxidant and nitrating species [27]. 
Peroxynitrite can cause protein tyrosine nitration as well as induce oxidative 
damage to proteins, DNA and lipids (Figure 2) [28]. It has been shown that the 
nitrotyrosine protein adducts were detected in vascular endothelial cells and 
parenchymal cells after APAP overdose before cell injury [29]. Both hydrogen 
peroxide and peroxynitrite decomposition products, OH and NO2 radicals 
can initiate LPO and lipid and protein nitration processes [30, 31]. These 
protein binding and LPO formation processes due to the ROS are crucial as 
they correlate with the initiating event of cell injury, which can be amplified 
through secondary processes [32]. One of the major secondary processes 
involved is mitochondrial dysfunction [33] which results in further ATP 
depletion, increased in oxidative stress and disruption of calcium homeostasis 





























































1.3.2.4 Amplification of mitochondrial oxidant stress 
 The direct attack of reactive metabolites/ROS on DNA, proteins and 
membrane lipids (including mitochondrial lipids) initiates mitochondrial 
dysfunction. With the absence of cellular GSH and increase in cytosolic 
reactive oxygen/nitrogen species (ROS/RNS), the mitochondrial ROS 
formation will be stimulated, leading to depolarization of the mitochondrial 
membrane potential, Δψm [36]. The decrease in Δψm confers elevation of 
mitochondrial ROS formation and mitochondrial membrane permeability 
transition (MPT) pore opening. This critical event will subsequently lead to 
the collapse of membrane potential, cessation of ATP synthesis, release of 
mitochondrial cytochrome c, endonuclease G and apoptosis-inducing factor 
(AIF) [37-39]. In the meantime, more of the generated ROS within 
mitochondria will be released into the cytoplasm, augmenting the intracellular 
ROS and subsequently amplifies the oxidative damage to the cell, establishing 
a vicious circle of oxidative damage. The mitochondrial oxidant stress and 
peroxynitrite formation will be further promoted when the c-jun-N-terminal 
kinase (JNK) was activated during intracellular stress [40]. The JNK 
activation leads to mitochondrial translocation of pro-apoptotic bax and P-
JNK [41] where the bax may aggravate the downstream process of MPT pore 
opening, e.g., extensive DNA fragmentation [42]. These processes eventually 
lead to both apoptotic and necrotic cell death [43, 44]. Taken together, protein 
binding and oxidant stress are sequential events rather than competing process 





1.3.2.5 Apoptosis and necrosis 
Apoptosis and necrosis are effector arms of liver injury, and therefore 
are good surrogate markers of the functional significance of any cytoprotective 
strategies. Apoptosis is orchestrated by a family of cysteine proteases known 
as caspases. There are two types of apoptosis, one involves the mitochondria 
intrinsic pathway while the other, independent of mitochondrial is known as 
the extrinsic pathway. In the event of intrinsic apoptosis, cytochrome c which 
is released from the intramitochondrial membrane, binds to a cytoplasmic 
scaffold (apaf-1) and pro-caspase-9 to form an apoptososme complex. 
However, as this is an energy-dependent process, it can only be activated 
when the MPT is not rapidly and simultaneously occurring in all mitochondria. 
In summary, only when some of the mitochondria are left intact and ATP 
synthesis remained, the executioner caspase-3 can be activated by pro-
caspase-9 and other pro-apoptotic mitochondria proteins [45]. On the other 
hand, the extrinsic pathway involves the binding of death ligands expressed by 
Kupffer cells upon apoptosis to the respective Fas/FasL, TNFR1/TNFα, and 
TRAIL-R1/TRAIL death receptors [46]. The downstream of death receptor 
signaling is associated with caspase-8 activation which either engages 
mitochondrial apoptotic signaling via truncated Bid or promotes apoptosis via 
activation of effector caspases (e.g., caspase-3) (Figure 3). Finally, both 
apoptosis pathway converged at the caspase-3 activation leading to cell death. 
Apoptosis is characterized by cytoplasmic and nuclear condensation and 
fragmentation without loss of membrane integrity.  
In contrast to apoptosis, necrosis occurs if the initial injury is too 
severe which results in causing MPT in all mitochondria and rapid ATP 
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depletion, preventing the apoptotic pathway. Necrosis can be characterized by 
cell and organelle swelling, extensive cell-content release which follow severe 
disturbance of cell functions and inflammation. Although it is debatable 
whether hepatic cell death is caused by apoptosis or necrosis, it is worth noting 
that there is not always clear-cut on the distinction between apoptosis and 
necrosis. Mixed phenomena have been described, and the same hepatotoxin 
may cause either one or the other, or even the concomitant occurrence of both, 
depending on the circumstances including dose, intensity of the injury, ATP 
availability of the cell and the pre-existing susceptibility of hepatocytes [47, 
48].   
In conclusion, mitochondria play a central role in determining the life 
and death of hepatotoxicity. They are the initial target of direct toxicity, the 
main source of intracellular ROS production, the MPT which plays a vital role 
in deciding the aggravation and further downstream injury pathway and 
because mitochondria generate most of the cells’ ATP supply, therefore the 
extent of mitochondrial impairment decides if the hepatocytes die by apoptosis 
or necrosis [49]. For this reason, an effective cytoprotective strategy must be 





































































Although each drug may cause distinctive features involved in liver 
injury, many drugs which cause direct hepatotoxicity share some common 
pathways in APAP-causing hepatic injury as discussed. Therefore, APAP-
induced liver injury is a good model to test and validate the effectiveness of 
new hepatoprotective agents. In general, the key steps involved in DILI 
comprises of: (1) drug metabolism and reactive metabolite formation in 
hepatocytes, (2) covalent binding, (3) ROS generation, (4) activation of signal 
transduction pathways that modulate cell death/survival in hepatocytes, (5) 
mitochondrial damage and (6) apoptosis or necrosis. In most cases, 
hepatocytes injury and death are the critical steps leading to the clinical 
manifestations of DILI. Owing to these fixed sets of mechanisms for most 
drug-induced toxicities, we establish our experimental framework to explore 




1.4 CELLULAR RESPONSES TO INJURY  
 
All cells possess some level of intracellular defense mechanism which 
can be triggered by a change in cellular homeostasis. Primarily, such defense 
is fronted by the cellular anti-oxidant response, which is activated in response 
to oxidative stress. A secondary activation of anti-apoptotic genes may also 
follow suit to protect the cells from excessive cell death. Even after cell death, 
cytokines as the key mediator in intrahepatic immune cells and hepatocytes 
may be activated to restore cellular homeostasis through regulating 
hepatocytes survival and regeneration pathway. Therefore, the concerted 
response of cellular defense mechanisms towards injury is important in 
determining the ultimate fate of hepatocytes undergoing injury. The intricacies 
of these biological responses should be considered whenever we explore the 







Although free radicals are continuously generated, the body is 
equipped to defend against the harmful effects of ROS with the help of 
antioxidants, collectively known as antioxidant defense system. The 
mechanistic function of these antioxidants can be classified into three 
categories, namely preventive antioxidants, scavenging antioxidants and repair 
and de novo antioxidants (Figure 4) [50].  
The first line defense involves the antioxidants in preventing the 
formation of ROS/RNS. The major antioxidants involved in this stage of 
catalytic removal of the ROS/RNS are catalase (CAT), superoxide dismutases 
(SOD), Gpx, glutathione-reductase (GSR), GSH and the metal chelating 
agents (e.g., transferrin, haptoglobin, hemopexin, etc.) [51]. SOD and CAT are 
the major antioxidants defense against ROS in this stage. For example, O2
   
formed in the mitochondria is dismuted into H2O2 by SOD, where the H2O2 is 
further reduced to water by CAT or Gpx. If free radicals were formed from the 
H2O2 and disturbed the redox balance in the cells, the second line of defense 
antioxidant will kick in.  
The aim of the second line defense scavenging antioxidants is to 
rapidly remove the active species before they attack the biologically essential 
molecules. This reduction of free radicals mechanisms were carried out by the 
electron donors such as GSH, lipophilic Vitamin E and flavanoids, hydrophilic 
Vitamin C, bilirubin and uric acid [52]. GSH is found in all eukaryotic cells 
and is one of the key non-enzyme antioxidants in the body. Due to its 
lipophilic nature, Vitamin E is an important and abundant antioxidant which 
protects cell membranes from LPO by scavenging lipid peroxyl radicals 
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(LOO) [53]. Finally, the third line defense involves the repair and de novo 
synthesis of antioxidants, such as lipase, protease, DNA repair enzymes and 
transferases where they repair damages formed, cleans the wastes and 
reconstituting the lost function in cells [51]. 
Although harmful in excess, physiological levels of ROS also act as 
signaling molecules. When the oxidative stress is triggered in cells, the 
antioxidant defense enzymes will be induced. In response to attack by 
electrophiles or ROS, nuclear factor erythroid 2-related factor (Nrf-2) is 
switched on and off via distinct mechanisms. Nrf-2 transcription factor 
regulates the expression of stress response proteins, such as heme oxygenase-1 
(HO-1). HO-1 is a stress response protein which is generally known to confer 
cytoprotection against oxidative stress [54, 55]. It is an essential enzyme 
which degrades heme into carbon monoxide (CO), biliverdin and free iron 
where the heme-derived metabolites served as a protective mechanism against 














Figure 4 Defense network against oxidative stress. Various antioxidants 




1.4.2 Anti-apoptosis  
Being major generators of ATP and sources of ROS in cells, damage 
or injury to mitochondria not only results in profound effects on ATP and 
ROS levels, it also causes the release of pro-death proteins such as cytochrome 
c, which affect both necrotic and apoptotic cell death [60]. Overall, the 
mitochondrial injury and MPT plays a central role in most of the DILI cases. 
The intricate process of such regulation hinges on mitochondrial apoptosis 
pathways, critically controlled by Bcl-2 family proteins, enclosing anti-
apoptotic (e.g., Bcl-2, Bcl-xL, Mcl-1), pro-apoptotic multidomain (e.g., Bax 
and Bak) and pro-apoptotic BH3-only proteins (e.g., Puma, Bad and Bid) [61]. 
In the liver, only two anti-apoptotic proteins, Bcl-xL and Mcl but not Bcl-2 
were expressed to protect hepatocytes from apoptosis [62]. Both Bcl-xL and 
Mcl-1 proteins act by suppressing the generation of ROS, preventing an 
increase in the permeability of mitochondria while blocking the release of 
cytochrome c [63]. Deficiency in either one of these anti-apoptotic proteins 
will result in caspase 3/7 activation and rapidly undergo mitochondrial 
dependent apoptosis [64, 65]. As a result, both Bcl-xL and Mcl-1 are crucial 
anti-apoptotic factors protecting hepatocytes from apoptosis induction while 






1.4.3 Liver inflammation 
Following severe acute liver injury (apoptosis or necrosis), a 
coordinated sequence of local (such as inflammatory response) and systemic 
changes is triggered. Collectively, these responses are known as the acute 
phase response (ACR) [66]. The purpose of ACR is to restore the disturbed 
physiological homeostasis by removing the cause of disturbance and repair the 
injury (Figure 5) [67]. Inflammatory processes are the main causes for the 
initiation of these defense mechanisms. At the early stage of liver injury, 
activation of the liver macrophages, Kupffer cells release pro-inflammatory 
cytokines such as tumor necrosis factor-alpha (TNF-), interleukin (IL)-1 and 
IL-6 at the site of damaged tissue [68, 69]. These cytokines are the most potent 
mediators of acute-phase protein synthesis in the hepatocytes [70, 71]. TNF- 
is known to activate activating protein-1 (AP-1) and nuclear factor-kappa B 
(NF-B) transcription factors. NF-B detected in macrophages and 
hepatocytes plays an important anti-apoptotic role [67, 72, 73]. On the other 
hand, activation of IL-6 receptor complex activates signal transducer and 
activator of transcription 3 (Stat3) transcription factor through JAK/STAT 
signal transduction pathway [74, 75]. In addition to that, mitogen activated 
protein kinase (MAPK) signal transduction pathway can be activated by either 
IL-6 or IL-1/TNF- signaling pathway (Figure 5) [74]. These transcription 
factors eventually bind to their response elements in the promoter regions of 
acute phase genes respectively and activate acute phase proteins secretion (see 
supplementary table 1). These acute phase proteins may operate as oxygen 
radical scavengers, protease inhibitors, coagulation factors and opsonins and 
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may therefore play a role in the non-specific defense of the host to infections 

























Figure 5 Acute phase response and induction of acute-phase protein 
expression by TNF- cytokines and IL6 cytokines respectively. (Adapted 
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1.4.4 Liver regeneration  
The last resolve of liver to overcome injury and cell death is to self-
regenerate. The liver is a unique organ that has great ability to regenerate after 
some toxic injury or hepatectomy [77, 78]. With partial hepatectomy (PH) 
where two thirds of the liver was removed, the remnant liver regenerates until 
the mass of the liver is restored [79]. During this regenerative process, 95% of 
quiescent hepatic cells can rapidly re-enter the cell cycle and proliferate. 
Hepatocyte regeneration proceed along a sequence of distinctive phases: an 
initiation or priming phase, rendering hepatocytes in a state of replicative 
competence; a proliferation phase, where expansion of the entire hepatocyte 
population takes place and a termination phase, where cell proliferation is 
suppressed to terminate regeneration at a defined set point.  
During initiation of liver regeneration, cytokines play a prominent role 
in inducing the quiescent hepatocytes from G0 phase to re-enter G1 phase in 
cell cycle [78]. It has been observed that TNF- and IL-6 cytokines were 
rapidly released after PH, leading to the activation of cytokine-regulated 
transcription factors such as NF-κB and Stat3 in the remnant liver (Figure 6) 
[80-82]. Animal models with the deficient in TNF receptor 1 (TNFR1) or IL-6 
cytokines and inhibition of NF-kB or Stat3 transcription factors demonstrated 
impaired liver regeneration [83-86]. Reciprocally, the activation of these 
transcription factors by TNF- and IL-6 cytokines results in both cellular 
proliferation and protection from cell death. On the other hand, NF-kB and 
Stat3 were also found to regulate the transcription of cyclin D1 which induced 
the cell-cycle transition from the G1 to the S phase [86, 87]. In addition to 
Stat3, IL-6 activates the MAPK signaling cascade which is crucial for cell 
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proliferation, and also the pro-survival kinases phosphoinositol 3 kinase (PI3K) 
and Akt pathway which are involved in hepatoprotection [88, 89]. 
After the progression of primed hepatocytes through G1 phase, the 
subsequent replicative cycling from G1 to S phase is mainly regulated by the 
hepatocyte growth factor (HGF) and transforming growth factor-alpha (TGF-
 signaling in the proliferative phase. Though epidermal growth factor (EGF) 
may be involved at the earliest proliferation phase [90], TGF-and HGF 
appeared to be the two potent mitogen for hepatocytes in culture at later times 
[91, 92]. These growth factors are important in stimulating DNA synthesis in 
hepatocytes [91, 93]. In addition to these growth factors, acidic fibroblast 
growth factor (FGF) and vascular endothelial growth factor (VEGF) were also 
expressed by the regenerating hepatocytes [94, 95]. Subsequent to the 
proliferative phase, the growth response is finally terminated when the liver is 
fully recovered. The inhibition of DNA synthesis were carried out by the most 
well-known hepatocytes anti-proliferative factors within the liver, TGF- and 





Figure 6 Schematic of the ‘start and stop’ signals during liver regeneration (Adapted from [97]). 
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1.4.5 Conclusion 
When the injury is too severe and the cellular responses are insufficient 
to protect or repair, the events of apoptosis or necrosis will eventually lead to 
liver failure. In view of this, besides preventing injury at prophylaxis stage, 
enhancing or strengthening the cellular defense responses and regeneration 
might present an alternative way to address the problem of DILI. 
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1.5 CURRENT MANAGEMENT IN DILI 
 
While the magnitude of the problem is well-appreciated, effective 
management has not been forthcoming. Current available strategies in dealing 





In recent years, there have been increasing research efforts on 
developing hepatoprotective agents for both hepatobiliary diseases and 
hepatotoxicities [98]. Apart from the newly emerged herbal remedies such as 
Bauhinia racemosa [99, 100], Capparis spinosa [101] etc., silymarin (SM) 
remains exclusive herbal remedies for hepatoprotection in the world since 16th 
century [102]. It has been reported that the antioxidant and free radical 
scavenging properties of SM counteracted LPO and GSH depletion but failed 
to affect the covalent binding caused by APAP intermediate [103]. Despite 
being widely used as hepatoprotectant, the administration of another 
xenobiotic to protect the liver is conceptually counter-intuitive, given that 
xenobiotics are the usual cause of liver injury. This poses additional challenge 




    
1.5.2 Treatment and limitations 
To date, cessation of drug use when ALT levels increase to more than 
3-5 times the ULN is the general management strategy for DILI. Treatments 
are available under exceptional circumstances such as the use of N-
acetylcysteine (NAC) for APAP poisoning. Even so, it is only effective when 
administered at an early stage, before extensive liver damage sets in [104]. 
Furthermore, prolonged treatment with NAC has been reported to impair liver 
regeneration in APAP-induced acute liver injury [105]. Apart from this, there 
are also toxicities with delayed onset, such as troglitazone where the 
hepatotoxicity only occurs several months after the use of the drug [106]. 
Hence, this makes association to the causative agent difficult and further delay 
appropriate responses, which then could abruptly develop hepatic failure. At 
the stage of liver failure, liver transplantation is mostly supportive.  
Against the wall of helpless observation when DILI occurs, the 
intuitive approach is to protect the remnant liver cells and prevent further 
worsening. The fact that there is no known universal protectant and the 
reliance on xenobiotics over the years to fulfill this role highlight the need to 
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1.6 PROPOSED STRATEGIES IN MANAGING DILI 
 
In view of the current limited management in DILI as mentioned above, 
it is important to protect the remnant liver cells and prevent further worsening 
when DILI occurs. There is currently no known universal protectant and the 
reliance on xenobiotics over the years highlights the need to explore potential 











Figure 7 Strategies in managing DILI. 
 
 
Referring to Figure 7, we proposed two strategies in managing DILI through: 
a) limiting injury at prophylaxis stage and  




    
1.6.1 Potential protective agent: alpha-tocotrienol (-T3) 
Prevention is always better than treatment. A good antioxidant could 
act as a protective agent in eliminating the unquenched reactive metabolites, 
thus limiting the injury. Vitamin E is well-known for its distinctive antioxidant 
properties and is the generic name for a group of fat-soluble compounds. It can 
be found naturally in many foods, fats and oils. Naturally, Vitamin E is made 
up of chemically distinct isoforms including four tocopherols (TP) and four 
tocotrienols (T3). Both TP and T3 are designated as and , depending 
on the number and positions of methyl groups on the chromanol ring. T3 are 
structurally quite similar to TP and differ only in having an unsaturated 
isoprenoid side chain rather than a saturated phytyl tail (Figure 8) [107]. TP 
generally exist in common sunflower oils and almonds while T3 are abundant 
in cereal grains and palm oil [108]. While the usefulness of Vitamin E as a 
health supplement has been known for a long time, there has been a 
resurgence of interest recently because increasing number of studies have 
reported that each of the compounds has varying levels of biological activity. 
Majority of the studies on Vitamin E were directed towards -TP, which is 
widely known for its antioxidant effect while T3 remain poorly understood. 
In the last decade, T3 studies have gained extensive momentum since 
they have been reported to possess numerous functions that were either not 
observed in TP or more potent than TP [109]. For instance, T3 has the 
cholesterol-lowering properties [110, 111], anticancer and tumor-suppressing 
activities, but not TP [112, 113]. Isoforms of T3, which contain different 
number of methyl groups, have different mechanisms of action and biological 
activities. Contradictory to some of the protective effects shown, - and -T3 
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have also been claimed in various studies to exhibit the most potent anticancer 
isoforms of all natural existing T3 [114, 115]. On the other hand, -T3 
demonstrated the most potent neuroprotection among Vitamin E analogues 
[116], was cardioprotective [117, 118] and had the ability to protect against 
stroke [119]. Importantly, -T3 also possessed more potent antioxidant 
properties than other T3 [120, 121] and -TP [122, 123]. These antioxidant 
properties are particularly important for the protection against oxidative stress 
which is caused by majority of the drugs resulting in liver injury. However, 
the potential protective effect of individual T3 analogs has never been 
explored in DILI. In light of its natural existence form and its powerful 
antioxidant properties, we hypothesize that -T3 could be the isoform 
exhibiting good protective effect against DILI. Therefore, the comparative 
effect against other isoforms deserves a formalized investigation. 
 




    
1.6.2 Potential regenerative agent: mesenchymal stem cells (MSC) derived 
exosomes 
Upon the onset of liver injury, stimulating the remnant liver to 
regenerate could help to recover the liver function. In the area of regenerative 
medicine, mesenchymal stem cells (MSC) based therapy has been extensively 
applied in the treatment of a variety of diseases due to its ability to 
differentiate and transdifferentiate, e.g., from osteoblast into adipocytes and 
chondrocytes [125], stimulate regeneration and repair damaged tissue/organs 
[126]. Researchers had demonstrated that different sources of stem cells were 
able to successfully enhance the recovery of acute hepatic failure in mice 
[127-129].  
 However, recent reports have shown that the reparative effects of MSC 
were mediated by the paracrine factors (bioactive molecules) secreted into the 
MSC-condition medium (MSC-CM) and these trophic factors stimulated host 
responses for repair even in the absence of MSC [130, 131]. This was first 
proven when Parekkadan et al., demonstrated that MSC-derived molecules 
successfully reversed the fulminant hepatic failure in mice [132]. This was 
followed by other promising cases using MSC-CM in overcoming APAP-
induced liver injury [133, 134] and CCl4 induced acute hepatic failure in mice 
[135]. Later, the mechanism of MSC-CM was further explored by Suomi et al., 
and was found to regulate liver recovery by promoting hepatocytes 
proliferation and regeneration in the early phase of PH [136]. Compared to 
MSC (cell-based) therapies, MSC-CM (non-cell-based) therapies are generally 
more preferable because it is less likely to trigger immune response and safer 
to use as they are nonviable. Moreover, MSC secretions being biologically 
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derived may exhibit minimum risk of xenobiotic-mediated toxicity that 
complicates the existing problem. This promising discovery of MSC-CM 
paved the way for a non-cell-based alternative for the treatment of liver injury.  
 Previously, proteomic and computational analysis on the MSC-CM 
revealed that the secretome in MSC-CM could potentially exert modulating 
effects on tissue repair and regeneration in cardiovascular, kidney and liver 
[137]. Subsequently, this hypothesis was tested in a myocardial 
infarction/reperfusion (MI/R) model and it was observed that cardiac function 
was preserved in the MSC-CM treatment group [131]. However, the active 
component in the MSC-CM and the mechanism of action in MI/R injury has 
not been elucidated in this study. Subsequently, Lai et al., fractionated the 
MSC-CM using HPLC and discovered that the therapeutic effect against MI/R 
comes from the fraction of particle size 55–100 nm in diameter, which is 
known as exosomes [138]. This study marked the first evidence in 
demonstrating exosomes as the major functional component in MSC-CM.  
 Due to some of these qualities, the exosomes appeared to be a more 
superior treatment than the conventional MSC therapy to explore for curbing 
liver injury. Since the exosomes were purified from MSC-CM, a well 
characterized and renewable source of hESC has been established for the 
generation of reproducible supply of MSC cultures. As a result, reproducible 
supply of consistent and uniform quality of CM and exosomes can be obtained. 
Notably, despite being a cell-derived therapy, no major histocompatibility 
complex (MHC) protein was found in these acellular exosomes [139], 
allowing them to evade from the immune system when engrafted across 
species.   
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 In view of the promising results of the above studies, the MSC-CM 
derived exosomes could also potentiate the repair effect in kidney and liver 
apart from the cardiovascular system. However, the hepatoprotective and/or 
hepatoregenerative effect by MSC-derived exosomes has never been 
demonstrated. Due to the unique regenerative ability, we would like to extend 
this study in exploring the potential effect of exosomes against DILI. 
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1.7 AIMS AND OBJECTIVES 
 
In view of the above review, it is worthwhile to explore potential 
therapeutic agents in the stage of preventing the injury, protecting the remnant 
liver cells from worsening damage, and stimulating the regeneration of the 
remnant liver cells when injury occurs. Given both liver regeneration and liver 
protection are equally important yet they act through different processes in the 
therapy of acute liver injury, we would like to explore exosomes and -T3 in 
managing DILI based on the research gaps below: 
 -T3 has been recently discovered to possess more potent antioxidant 
properties than -TP and other T3 analogs but its antioxidant effect 
and the relative advantage vs other analogs has yet to be explored in 
the DILI model.  
 The postulation on the proteomic study of MSC-CM of its potential 
regeneration effect in heart, kidney and liver has been proven in mice. 
Although the major functional component in MSC-CM has been 
identified as exosome and was proven in MI/R model, the 
hepatoregeneration effect of exosomes has never been demonstrated in 
the DILI model. 
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Figure 9 Summary of proposed aim and management approaches to 
overcome DILI. 
 
The main aim of this study was to explore the potential 
regenerative/protective effect of MSC-derived exosomes and -T3 in 
overcoming DILI and other acute liver injury models (Figure 9). Thus, the 
specific objectives of this research were to: 
1. Investigate cytoprotective effect of exosomes in vivo model of drug-
induced and acute liver injury model. 
2. Study the in vitro effect of the exosomes on different hepatotoxicants with 
different mechanism of toxicities. 
3. Explore potential target pathways of hepatoprotection or 
hepatoregeneration of exosomes. 
4. Study the in vitro effect of the T3 analogs compared to -TP on different 
hepatotoxicants with different mechanism of toxicities. 
5. Explore potential target pathways of hepatoprotection or 
hepatoregeneration of the effective T3 analog(s) compared to -TP. 
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The results of this present study may have significant impact on 
providing an alternative therapeutic solution against DILI. This may also 
extend our understanding of the mechanistic insights on how each agent 
affects the recovery/injury processes in the liver, and if these agents have the 
ability to mitigate the acute liver injury in vitro as well as in vivo. 
In order to substantiate the therapeutic effect of exosomes in mice, it is 
important to prove the delivery of exosomes into the liver. However, this is 
beyond our current detection means because the injected amount might be too 
little to be detected and they might get metabolized in the liver in a short time 
frame and excreted out from the body. Besides that, the formulation of -T3 
on increasing its bioavailability in mice is undergoing and thus it is not 
available during the time frame of this thesis. Though important, exploring 
potential therapeutic effect of -T3 in vivo is not within the scope of the 
present study. Since this is an exploratory study on the therapeutic effect of 
exosomes and T3 analogs in DILI, concurrent treatment will first be carried 
out. Upon confirming their therapeutic effect, the post-treatment should then 









 Materials and Methods 
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2 .1 MATERIALS 
 
Dulbecco’s modified Eagle’s medium (DMEM), dexamethasone, nicotinamide, 
gentamicin, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT), olive oil, collagen-I , monochlorobimane (MCB), L-glutathione 
reduced (GSH) and glutathione-S-transferase (GST) were obtained from 
Sigma Chemical Co. (St. Louis, MO). Dulbecco’s modified Eagle’s 
medium/Ham’s F12 (DMEM/F12), LHC-9 medium, JC-1 and Superscript III 
First-strand Synthesis System were products of Invitrogen (Carlsbad, CA). 
Insulin, transferrin, selenium (ITS) were bought from BD (Franklin Lakes, NJ). 
Fibronectin was obtained from Millipore (Billerica, MA). Fetal bovine serum 
(FBS) was purchased from Thermo Fisher Scientific Inc. (Waltham, MA). 
Chloromethyl derivative of 2',7'-dichlorodihydrofluorescein diacetate (CM-
H2DCFDA) was bought from Life Technologies (Carlsbad, CA).  OxiSelect™ 
Thiobarbituric acid reactive substances (TBARS) Assay Kit (Malondialdehyde 
(MDA) Quantitation) was purchased from Cayman Chemical (Ann Arbor, MI).  
Caspase-Glo® 3/7 assay kit was bought from Promega (Madison, WI). 
Dimethylsulfoxide (DMSO) was obtained from Merck (Darmstadt, Germany). 
SYBR Green PCR master mix was obtained from Applied Biosystems 
(Warrington, UK). DNA-free
TM
 kit was from Ambion (Austin, TX). RNeasy
®
 
mini kit and QIAshredder were products of Qiagen (Hilden, Germany). All 
primers were synthesized by 1
st
 BASE Oligos (Singapore). Primary antibodies 
were purchased from the following companies: phospho (Tyr705)-STAT3, 
PCNA, NF-B p65, cyclin D1 and cyclin E, Cell Signaling Technology 
(Danvers, MA); Bcl-xL (H-5), Nrf-2 (C-20), p-Met (Tyr 1234), Santa Cruz 
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Biotechnology (Dallas, TX); HO-1, Enzo Life Science (Farmingdale, NY); 
HGF and -actin, Abcam (Cambridge, UK). MSC-derived exosomes was 
obtained from Dr. Lim Sai Kiang (IMB, A*STAR, Singapore) and -TP and 
T3 analogs were obtained from Dr Fong Chee Wai (Davoslife, Singapore).   
 
2.1.1 Preparation and quantification of MSC-derived exosomes  
hESC-derived HuES9.E1 MSCs were used for the production of MSC 
secretion in the form of CM as described [138]. The exosomes preparation and 
purification process were done by the Bioprocessing Technology Institute 
(BTI) and provided by Dr. Lim Sai Kiang (IMB, A*STAR, Singapore). To 
harvest MSC secretion, 80% of the conﬂuent HuES9.E1 cultures were washed 
with phosphate buffered saline (PBS), transferred to a chemically deﬁned, 
serum-free culture medium for an overnight incubation, washed with PBS and 
cultured in fresh, chemically deﬁned, serum-free culture medium for 3 days. 
The CM which contained MSC secretion was collected, clariﬁed by 
centrifugation, and was concentrated 50x by tangential flow filtration (TFF) 
using a membrane with a 100 kDa MWCO (Sartorius, Goettingen, Germany). 
CM was fractionated by high performance liquid chromatography (HPLC) 
(TSK Guard column SWXL, 6x40 mm and TSK gel G4000 SWXL, 7.8x300 
mm, Tosoh Corp., Tokyo, Japan). Exosomes were collected from the first peak 
of the elution and concentrated using 100 kDa MWCO filter (Sartorius). 
Exosomes were filtered with a 0.22 µm filter and stored in -20ºC freezer until 
use.  
The identity of the exosomes used in this study had been previously 
characterized by Lai et al., [138]. In short, quantification of exosomes was 
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done through protein assay of the exosomes lysates. The variability of 
exosomes quality from batch to batch was controlled and assured through the 
measurement of several parameters as previously described [138]. These 
include the physical properties, e.g., the HPLC retention time, dynamic light 
scattering value (hydrodynamic radius), isoelectric focusing (pI value), and 
sucrose gradient density test (floatation density). Finally the exosomes were 
subjected to a mouse MI/R model to evaluate its cardioprotective effect [138]. 
Only the effective batches of exosomes with similar outcome were used in this 
study. 
 
2.1.2 Preparation and quantification of Vitamin E derived -TP and T3 
T3 and TP isomers were provided by Davos Life Science Pvt. Ltd., Singapore. 
The appearance of the pure compounds was oily liquids. They were dissolved 
in absolute ethanol (100 mM) and stored at −20°C. Using the corresponding 
T3 isomers as the reference standard, the purity of T3 and -TP isomers was 





    
2.2 IN VIVO STUDIES 
 
2.2.1 Animal and diets 
Six-week-old male C57BL/6 mice (21-27 g) were supplied by the Lab 
Animals Centre, Singapore. Animal were housed in animal holding unit in 
National University of Singapore (NUS) at a constant temperature in a 12/12-
hr light/dark cycle. All animal procedures were carried out according to 
09/123 protocol number approved by Institutional Animal Care & Use 
Committee NUS (IACUC). The mice were acclimatized for 2 weeks prior to 
use where the mice were 8 weeks of age at the time of experiments. Prior to 
experiment, mice were allowed for free access of food and water. 
 
2.2.2 In vivo CCl4 induced liver injury model optimization 
For ALT over time profile, 0.05 ml/kg of CCl4 dissolved in olive oil (3% v/v) 
was injected through intraperitoneally (i.p). 20 l of blood was collected via 
tail vein at 0, 12, 24, 36, 48, 60 hr and cardiac puncture was performed at 72 
hr when mice were sacrificed. In the development of CCl4 injury model, mice 
were divided into 4 groups of three each. In experiments on optimizing CCl4 
concentration, 0, 0.05, 0.1 and 0.2 ml of CCl4/kg body weight of mousewhile 
0.2 ml/kg of olive oil as vehicle control was administered i.p. 24 hr. Later, 
mice were sacrificed under carbon dioxide (CO2), blood sample collected from 
cardiac puncture was used for determination of plasma ALT activities. 
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2.2.3 In vivo exosomes route of administration optimization 
Total 100 l of 0.4 g exosomes (4 g/ml) in PBS was injected through i.p or 
intrasplenic (i.s). The blood was collected 24 hr later for ALT assay.  
 
2.2.4 CCl4 induced acute liver injury induction with exosomes treatment 
Six mice per group were weighed before CCl4 treatment. All mice were 
treated with 0.05 ml/kg CCl4 (3% v/v in olive oil) via i.p for each trial as 
mentioned above. 0.4 g (100 l) exosomes or 100 l PBS were administered 
through i.s for treatment group and vehicle control group respectively. Blood 
was collected via cardiac puncture after 24 hr of treatment. Blood samples 
were withdrawn for the estimation of ALT activities. Following collection of 
blood sample, the livers were immediately removed into several parts, a 
portion was snap frozen in liquid nitrogen and stored at -80 
0
C for later 
ribonucleic acid (RNA) isolation and protein extraction while another portion 




    
2.2.5 Measurement of serum ALT and aspartate aminotransferase (AST) 
release 
Plasma of 5 l was obtained by centrifugation of the heparinized blood at 800 
g for 10 min. At different time points of CCl4-induced hepatic injury, the ALT 
activities were measured using an ALT activity assay kit (Biovision, 
California) performed according to the manufacturer’s protocol. This method 
of analysis was optimized for handling very small volumes collected via tail 
vein. The absorbance was read at 450 nm using a Tecan
R
 microtiter plate 
reader. For the blood collected through cardiac puncture, the ALT and AST 
activites were read using the Cobas® 4000 analyzer.  
 
2.2.6 Histologic examination  
Liver specimens were obtained from six mice each group. Each liver specimen 
from one mouse was divided into two sections. They were respectively used 
for gross histologic examination, Western blot and immunohistochemical 
analysis. Samples of liver were fixed in 10% formaldehyde and then 
dehydrated and embedded in paraffin. Sections were cut from each paraffin-
embedded tissue and stained with haematoxylin & eosin (H&E). The extent of 
necrosis was evaluated based on a grading score (Grade 1 to 5) as follows: 
Grade 1 (minimal necrosis); Grade 2 (mild necrosis); Grade 3 (moderate 
necrosis); Grade 4 (marked necrosis) and Grade 5 (severe necrosis). Scanning 
and image analysis was performed by the Advanced Molecular Pathology 
Laboratory, IMCB, Singapore. 
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2.2.7 Immunohistochemistry (IHC) of PCNA 
Every liver specimen from one mouse was divided into two sections. The 
sections of liver from the mice in different groups were immunostained with a 
monoclonal antibody to mouse PCNA. Slides were scanned at 20x using a 
Leica SCN400 slide scanner (Leica Microsystems, Germany). Images were 
exported to Slidepath Digital Image Hub (Leica Microsystems, Germany) for 
viewing. Tissue sections were analysed using Measure Stained Cells algorithm 
of Slidepath TissueIA software (Leica Microsystems, Germany). Data was 
collated using Microsoft Excel. Scanning and image analysis was performed 
by the Advanced Molecular Pathology Laboratory, IMCB, Singapore. The 
outcome of cellular H-Score was defined as (% of weakly stained cells x1 + % 





    
2.3 IN VITRO STUDIES 
 
2.3.1 Cell lines and culture conditions  
Immortalized murine transforming growth factor alpha (TGF-α) transgenic 
hepatocyte (TAMH) cells [21], (obtained as a kind gift from Prof Nelson 
Fausto, University of Washington, USA), was used as a metabolically 
competent liver cell line that reproduced drug bioactivation and features of 
cytotoxicity to support this investigation. These cells maintained normal 
hepatocyte morphology and remained non-tumorigenic even after prolonged 
passages and culturing [22]. TAMH cells were maintained in DMEM/F12 
(Gibco) supplemented with 5 mg/ml insulin, 5 mg/ml transferrin, 5 ng/ml 
selenium (BD), 100 nM dexamethasone, 10 mM nicotinamide and 0.01% (v/v) 
gentamicin (Sigma). In a 96 well plate, TAMH cells were seeded at a density 
of 1.5 x 10
4
 cells/well in 200 l DMEM/F12 medium overnight before 
toxicant treatment. In a 6-well plate, TAMH cells were seeded at a density of 1 
x 10
6
 cells/well for quantitative real-time polymerase chain reaction (qRT-
PCR).  
HuH-7, a human hepatocarcinoma cell line obtained from HSRRB (Tokyo, 
JAPAN), was grown in DMEM (Sigma) supplemented with 10% FBS 
(Hyclone). In a 96-well plate with treatment for 72 hr, HuH-7cells were 
seeded at a density of 5 x 10
3
 cells/well while for a 24 hr treatment, cells were 
seeded at a density of 7.5 x 10
3
 cells/well in 200 l DMEM medium overnight 
before toxicant treatment.   
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THLE-2, a human normal liver cell obtained from ATCC (Manassas, VA), 
was cultured in LHC-9 medium supplemented with 10% FBS (Hyclone). This 
cell line was selected because of its functional metabolic competency [140]. 
The flasks used were pre-coated with a mixture of 0.01 mg/ml fibronectin, 
0.03 mg/ml bovine collagen type I and 0.1 mg/ml bovine serum albumin (BSA) 
dissolved in LHC-9 basal medium. In a 96-well plate, THLE-2 cells were 
seeded at a density of 1 x 10
4
 cells/well in 200 l LHC-9 medium overnight 
before toxicant treatment.   
 
All the three cell lines were maintained at 37 
0
C in a humidified 95% air and 5% 
CO2 atmosphere. Cells were passaged at 80-90 % confluency. 
 
2.3.2 In vitro cytotoxicity test of exosomes and Vitamin E analogs (-TP and 
T3 isomers) 
TAMH, HuH-7 and THLE-2 cells were treated with various concentrations of 
exosomes in respective culturing medium for 24 or 72 hr. Cell viability assays 
were performed after the respective incubation time to determine the 
cytotoxicity of exosomes.  
 
TAMH cells were treated with various concentrations of Vitamin E analogs  
for 24 hr and cell viability assay was performed to determine the cytotoxicity 
of each analog. 
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2.3.3 In vitro cellular uptake of Vitamin E analogs (-TP and T3 isomers) 
4 x 10
6 
TAMH cells were seeded into T-75 flask and incubated overnight. 
Cells in each flask which contained 15 ml of DMEM/F12 medium were 
treated with 5 M, 10 M, 25 M, 50 M and 100 M of each analog for 24 
hr. Then, cells were harvested and the cell pellets were resuspended in PBS. 
The cells were washed twice. Thereafter, each sample cell pellet was lysed in 
400 l of lysis buffer (1% Triton X-100, pH 7.5, 20 mM HEPES buffer with 
0.1 mM EDTA). 1 ml of 0.01% BHT (anti-oxidant) ethanol solution and 0.01 
mg 2,2,5,7,8-pentamethyl-6-chromal (PMC) as internal control were added 
into the lysates. 3 ml of hexane were then added and the mixtures were 
vortexed for 5 min and centrifuged at 4000 rpm for 10 min. The cellular 
Vitamin E in the upper hexane layer were extracted, dried, reconstituted and 
analyzed with HPLC using Lichrospher Si 60, 250 x 4 mm, 5 m cartridge 
normal phase column attached to fluorescence detector (FLD) and diode array 
detector (DAD) detector. Each α-TP or T3 was obtained by collection of each 
peak fraction during HPLC. The amount of α-, γ- and δ-T3 and α-TP were 
quantified on the basis of each peak area. 
 
2.3.3 In vitro APAP-induced liver injury model 
Each cell line was treated with various concentrations of APAP at respective 
time and the concentration which gives 50% cell viability (LC50) was used.  
 
TAMH cells were treated with 2 mM APAP and various concentrations of 
exosomes or -T3 (with 0.1% ethanol as background) for 24 hr before the cell 
viability test was performed.  
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HuH-7 and THLE-2 cells were treated with 5 mM and 3.5 mM APAP 
respectively with various concentrations of exosomes for 72 hr before 
performing the cell viability test.  
 
2.3.4 In vitro hydrogen peroxide (H2O2)-induced liver injury model 
Each cell line was treated with various concentrations of H2O2 for 24 hr and 
the concentration is adjusted to achieve 50% cell viability (LC50) in order to 
establish the liver injury model.  
 
In TAMH cells, 350 M H2O2 was treated with various concentrations of 
exosomes or -T3 (with 0.1% ethanol as background) for 24 hr before 
performing the cell viability test.  
 
In THLE-2 cells, 100 M H2O2 was treated with various concentrations of 
exosomes for 24 hr before performing the cell viability test. 
 
HuH-7 cells were treated with 60 M H2O2 with various concentrations of 




    
2.3.5 Cell viability assay  
Following incubation of toxicants with different concentrations of exosomes 
or -T3 in 96 well plates, the cell viability (10 replicates per treatment) was 
evaluated by the MTT assay (Sigma). 20 ml of 5 mg/ml MTT were dissolved 
in PBS. After the incubation period, the media was aspirated and the formazan 
crystals in cells were dissolved in 200 l of DMSO and 25 l of Sorenson’s 
buffer [141]. The absorbance was read at 570 nm using a Tecan
R
 microtiter 
plate reader. Cell viability percentage was expressed as a ratio of cells exposed 
to different concentrations of toxicants with those of vehicle controls.  
 
2.3.6 Isolation of total mRNA from TAMH cells 
Total cell RNA was prepared using RNeasy columns (Qiagen, Valencia, CA). 
The quality and quantity of total RNA was determined (OD 260/280 within 
1.8-2.1) with NanoDrop (Thermo, Wilmington, DE). 
 
2.3.7 Reverse transcription and qRT-PCR 
First-strand cDNA was synthesized from 1 g total RNA using Superscript 
First-Strand Synthesis System according to the protocols of the manufacturer. 
qRT-PCR was performed using BioRad CFX96 real time PCR system with 
SYBR Green master mix and primers as shown in Table 1. Triplicates were 
prepared with 4 l of 10 fold-prediluted cDNA. The thermal cycling condition 
comprised an initial denaturation at 95 
0
C (10 mins), followed by 40 cycles at 
95 
0
C (15 s) and 60 
0
C (60 s). Melting curves were generated at the end of 40 
cycles to verify the purity of the PCR product. Data were obtained as average 
Ct values, and normalized against the geometric mean of GAPDH endogenous 
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controls as  Ct. Transcript differences between exosomes or -T3 treated 
group and non-treated group were measured as fold changes using the 
comparative Ct method. Statistical analysis of RT-PCR was performed using 
REST software, Qiagen. 
 
 
Table 1 Sequences of primers used in real time PCR reaction 
Gene Forward primer (5’-> 3’) Reverse primer (5’-> 3’) 
In vitro hepatocytes (TAMH cells) 
TAMH-TNF- ATG AGC ACA GAA AGC ATG 
ATC 
TAC AGG CTT GTA ACT CGA 
ATT 
TAMH-IL-6 AGT TGC CTT CTT GGG ACT GA TCC ACG ATT TCC CAG AGA 
AC 
TAMH-iNOS CAC CTT GGA GTT CAC CCA GT ACC ACT CGT ACT TGG GAT 
GC 
TAMH-COX-2 CTC CCT GAA GCC GTA CAC AT GCT CGG CTT CCAA GTA 
TTG AG 
TAMH-MIP-2 AAG TTT GCC TTG ACC CTG AA AGG CAC ATC AGG TAC GAT 
CC 
TAMH-HO-1 CAG GTG ATG CTG ACA GAG 
GA 
ATG GCA TAA ATT CCC 
ACT GC 
TAMH-Gpx4 CCG GCT ACA ACG TCA AGT 
TT 
CGG CAG GTC CTT CTC 
TAT CA 
TAMH-GSR ACC ACG AGG AAG ACG AAA 
TG 
GGT GAC CAG CTC CTC 
TGA AG 
TAMH-MnSOD GGC CAA GGG AGA TGT TAC 
AA 
CCT TGG ACT CCC ACA 
GAC AT 
TAMH-GAPDH GGC ATT GCT CTC AAT GGAC 
AA 





    
2.3.8 Western blots 
For animal studies, mouse liver tissue was homogenized using glass Dounce 
homogenizer. Cells were lysed with 800 l of lysis buffer containing 50 mM 
HEPES pH 7.5, 150 mM NaCl, 1 mM EDTA, 10% glycerine, 1% Triton-X, 
0.5 M sodium fluoride, 100 mM sodium orthovanadate, 100 mM PMSF and 
20 mg/ml aprotinin. For cell culture studies, TAMH cells were seeded at 2 x 
10
6
 in a 10 cm dish with DMEM/F12 medium overnight. The medium was 
changed to DMEM/F12 low glucose and cells were cultured for 2 days. Cells 
were then treated with respective concentration of APAP or H2O2 and 
exosomes for 24 hr. All cells were harvested for Western blot analysis. Cell 
pellets were lysed with 100 l of RIPA lysis buffer containing 50 mM Tris, 
150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP-40, 0.5 M 
sodium fluoride, 100 mM sodium orthovanadate, 100 mM PMSF and 20 
mg/ml aprotinin. 40 g total protein per mouse sample and 10 g per cell 
sample were resolved in 10% SDS-PAGE and immobilized on PVDF 
membrane. The membranes were blocked in 5% non-fat milk for 1 hr and 
incubated in respective primary antibodies overnight (pSTAT3 1:1000; pMet 
1:400; NF-B 1:2000; Bcl-xL 1:1000; PCNA 1:10000 cyclin D1 1:1000; 
cyclin E 1:1000;  HO-1 1:1000; Nrf-2 1:2000 and HGF 1:500), followed by 
respective secondary antibody (1:10000) incubation for 1 hr. All membranes 
were visualized using chemiluminescence substrate (Pierce Biotechnology, 
Rockford, IL). The bands intensities were normalized against actin and were 
quantified using ImageJ software [142, 143]. 
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2.3.9 Determination of GSH content 
2 x 10
6 
TAMH cells were seeded into 6 well plate overnight. TAMH cells 
were treated with 2 mM APAP or 450 M H2O2 concurrently with 10 M or 
50 M of -TP or -T3 for 24 h. Cells were harvested and washed with PBS 
twice. 200 l of lysis buffer (0.1 % Triton-X/1M Tris/HCl) were added. The 
cells were sonicated in an ultrasonic bath for 5 min and incubated in ice for 15 
min before centrifugation. 10 l of each supernatant or GSH standard were 
added into each well in a 96 well plate in duplicate. 90 l of the MCB and 
GST mixture (final concentration 10 nmol of MCB and 0.1 unit of GST) were 
added into each well. The plate was incubated at 37
0
C for 60 min before the 
contents were measured using fluorescent plate reader with excitation 
wavelength at 380 nm and emission wavelength at 470 nm. 
 
2.3.10 Determination of intracellular reactive oxygen species (ROS) 
Total of 25 x 10
3 
TAMH cells were seeded into 96 well plate overnight. 2 mM 
APAP or 450 M H2O2 were treated concurrently with 10 M or 50 M of -
TP or -T3 for 24 hr. The cells were then incubated with 25 µM CM-
H2DCFDA for 45 min at 37
0
C and washed three times with PBS. The plate 
was measured using fluorescent plate reader with excitation wavelength at 485 
nm and emission wavelength at 535 nm. Levels of intracellular ROS were then 




    
2.3.11 Determination of intracellular lipid peroxidation (LPO)  
Total of 4 x 10
6 
TAMH cells were seeded into T-75 flask overnight. 2 mM 
APAP or 450 M H2O2 were treated concurrently with 50 M -TP or -T3 
in each flask for 24 hr. The cellular MDA level was determined with a 
TBARS assay kit performed according to the manufacturer’s protocol. The 
MDA levels were measured using fluorescent plate reader with excitation 
wavelength at 530 nm and emission wavelength at 540 nm. 
 
2.3.12 Determination of membrane potential transition (MPT) 
Total of 1.5 x 10
4
 TAMH cells/well were seeded in a 96 well plate for 
overnight. 2 mM APAP or 450 M H2O2 were treated concurrently with 10 
M or 50 M of -TP or -T3 for 24 hr. Medium were aspirated and the cells 
were incubated with 5 M JC-1 at 370C for 60 min. Cells were then washed 
twice with PBS and 100 ml of PBS were added into each well. Red 
fluorescence (excitation 550 nm, emission 600 nm) and green fluorescence 
(excitation 485 nm, emission 535 nm) were read using fluorescence plate 
reader with multiple reads per well (mrpw) setting. Ratios of red fluorescence 




    
2.3.13 Caspase-3 activity assay 
Total of 25 x 10
3
 TAMH cells were seeded into 96 well plate overnight. 2 mM 
APAP or 450 M H2O2 were treated concurrently with 10 M or 50 M of -
TP or -T3 for 24 hr. The caspase 3/7 level was determined with a Caspase-
Glo®3/7 Reagent assay kit performed according to the manufacturer’s 
protocol. The caspase 3/7 levels were in relative to respective groups of cell 
number. 
 
2.3.14 Combination therapy 
Total of 1.5 x 10
4
 TAMH cells/well were seeded in a 96 well plate for 
overnight. 2 mM APAP or 450 M H2O2 were treated concurrently with 0.1 
g/ml of exosomes or 50 M of -T3 for 24 hr. Cell viability were assessed 
using cell viability (MTT) assay under section 2.3.5. 
 
2.3.15 Statistical analysis 
All quantitative data were expressed as means ± standard error of means (SEM) 
and analyzed using Student’s two-tailed T-test. One way ANOVA with Tukey 
post-hoc analysis was performed when there were more than two groups for 
comparison. Statistically significant difference was defined at p-values of less 













    
3.1 INTRODUCTION   
 
 In this study, we hypothesized that the size purified subset of exosomes 
derived from MSC-CM can play a role in mitigating xenobiotic-induced liver 
injury. Since the hepatoprotection or hepatoregenerative effect of MSC-
derived exosomes has never been demonstrated, we first explore the protective 
or regenerative effect of exosomes in vivo using CCl4-induced liver injury 
model followed by exploring its mechanism of action in the in vitro study 
using well-established APAP- and H2O2-induced liver injury models. 
 
 
3.2 INFLUENCE OF EXOSOMES AGAINST CCL4-INDUCED LIVER INJURY IN 
VIVO MODEL 
 
As a proof of concept, the effects of exosomes were first studied in 
vivo using a classical model of acute liver toxicity, i.e., CCl4-induced hepatic 
injury in mouse. This model was adopted in our in vivo study because it has 
been one of the most established and widely used liver injury models today. 
Before the actual experiment, development of CCl4 mouse model was 
carefully calibrated in order to obtain the CCl4 ALT profile representative of 
acute liver injury. This was followed by the screening of exosomes toxicity in 




    
3.2.1 Development of CCl4-induced hepatic injury in a mouse model  
Firstly, an ALT time course for CCl4 was assessed in order to ascertain 
the timepoint where ALT is at its peak. This was done through injecting 0.05 
ml/kg of CCl4 through i.p at time 0, followed by blood collection through tail 
vein at designated time points up till 72 hr post-dose. A preliminary 
experiment revealed that serum ALT gradually increased and peaked at the 24 
hr after a single dose of CCl4 (Figure 10A). Thus, AST and ALT were 
measured at 24 hr after respective treatments.  
Subsequently for the CCl4 dosage optimization, ALT levels were 
measured at 24 hr after single dose of 0.05, 0.1 and 0.2 ml/kg CCl4. In general, 
healthy liver mounts a proportional compensatory regeneration on exposure to 
sub-lethal doses of hepatotoxicants. At high doses, liver regeneration will be 
inhibited and coupled with rapid and irreversible injury resulting in liver 
failure [144]. We observed the same peak ALT level at 24 hr in high dose of 
CCl4 compared to the lower dose (data not shown). From Figure 10B, the ALT 
level increased with higher dosage and there was a huge rise in the ALT 
starting from the lowest dose of 0.05 ml/kg compared to the olive oil as 
vehicle control. Since CCl4 is a potent toxicant in causing severe injury to the 
liver with little amount, thus the lowest concentration of 0.05 ml/kg CCl4 
which gives around 2,000 U/L ALT reading (which is 20X ULN) was chosen 
for the subsequent in vivo experiments. Overall, it was found that that the ALT 
increased in a time and dose dependent manner in this CCl4 model. 
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Figure 10 ALT over time profile for CCl4 and dose-dependent CCl4 
induced liver injury model in mice. C57Bl/6 mice were treated with (A) 0.05 
ml/kg concentration of CCl4; serum level of ALT activity was determined at 6, 
12, 24, 36, 48, 60 and 72 hr after injection and (B) 0.05, 0.1 and 0.2 ml/kg 
concentration of CCl4 or olive oil as vehicle control; serum level of ALT 
activity was determined at time 24 hr after injection. Results were shown in 













































    
3.2.2 Screening of exosomes toxicity and the optimum route of exosomes 
administration in a mouse model 
Based on a previous study performed by our collaborator [138], 0.4 g 
of exosomes/mice was proven to be sufficient in generating positive outcome 
in protecting against MI/R in a mouse model. Therefore the same amount of 
exosomes was adopted in this study as a starting point to perform the 
exosomes cytotoxicity screening. Exosomes were injected through two 
different routes of administration, i.s as well as i.p. Injection through spleen 
has been widely used in liver experiments [145, 146]. This is because spleen 
has a rich blood supply which is directly accessible to hepatic portal 
circulation that could lead to rapid accumulation of transplanted liver cells to 
the liver [147]. The blood was collected 24 hr later for ALT assay. As shown 
in Figure 11, none of the routes of administration or the dosage of exosomes 
caused significant increase in ALT level compared to the controls. This 
suggests that the exosomes cause no observable cytotoxicity to the liver; 
neither does the route of administration affects the liver injury level. Even 
though administration of exosomes through i.p did not cause elevation in ALT, 
it is conceivable that most of the exosomes administered could be diffused and 
distributed via the vasculatures in the peritoneal organs and even pre-
systemically eliminated. To rule out this possibility and uncertainty, 
administration of exosomes through i.s was adopted in the following 
experiments as this method is the most direct method in delivering the 














Figure 11 Exosomes cytotoxicity in mice. 0.4 g/mice of exosome were 
treated in C57Bl/6 mice through i.s or i.p. Serum level of ALT activity was 
determined at time 24 hr after injection. 3x ULN indicates the threshold for 
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3.2.3 Effect of exosomes on CCl4 induced biochemical indices of injury  
In a liver function test, biochemical markers such as AST and ALT are 
often used to indicate liver damage. These enzymes were elevated when there 
is tissue or organ damage. ALT remained as the gold standard biomarker of 
liver injury while AST is supplementary as it may also be indicative of other 
organ damage (e.g., cardiac tissues). Thus the AST and ALT were first 
evaluated to confirm the protection effect of exosomes against CCl4. 
0.05 ml/kg of CCl4 (in olive oil) was first injected into 8 weeks old 
mice through i.p followed by the 0.4 g of exosomes (in PBS) administration 
through i.s. There were 6 mice in each group and they were euthanized after 
24 hr of treatment. The liver and blood were harvested; AST and ALT in the 
blood serum were measured. From Figure 12A&B, group of mice receiving 
0.05 ml/kg CCl4 demonstrated significant increased in AST and ALT within 
24 hr of dosing. In contrast, in mice treated with CCl4 and exosomes group, 
the level of AST and ALT after 24 hr was significantly less than the CCl4 
group. Overall, exosomes conferred protection against CCl4 therefore limiting 
the extent of injury. This observed protective effect is not due to the chemical 
interactions between CCl4 and exosomes because they were spatially 
segregated at the point of administration. 
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Figure 12 Effect of exosomes on biochemical parameters after CCl4 
treatment in vivo. Serum (A) AST and (B) ALT level were measured after 24 
hr dosing of CCl4 with or without exosomes administration. n=6 per group; # 
p<0.05 for CCl4 versus of vehicle control; * p<0.05 versus of CCl4 alone for 
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3.2.4 Effect of exosomes against CCl4 on histopathological patterns of liver 
injury  
To further substantiate the protective effect of exosomes against CCl4, 
the extensive hepatic necrosis level was evaluated. Liver morphology was 
assessed by H&E staining on the paraffin-embedded liver tissue. 
Histologically, CCl4 group showed moderate hepatic necrosis while minimum 
necrotic cells were observed in the exosomes treatment group (Figure 13A-C). 
This result indicates that exosomes limit the extent of injury caused by CCl4. 
Exosomes treatment group also demonstrated minimal inflammation 
compared to CCl4 treatment group. Therefore, exosomes can attenuate 
inflammatory responses. There is no evidence that exosomes alone can 
modulate immune response in mouse liver. 
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Figure 13 Effect of exosomes on hepatocyte injury after CCl4 treatment in 
vivo. Representative H&E staining for liver tissue harvested after 24 hr of (A) 
CCl4 administration and (B) CCl4 with exosomes treatment. n=6 for each 
group. There is obvious hepatic necrosis (white arrow) in the section from 
CCl4-treated animal. Original magnification x 80; scale bar = 100 m. (C) 
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3.2.5 Effect of exosomes against CCl4 on protein expression in liver 
regeneration  
As reported by Herrera et al., and Suomi et al., secreted factors derived 
from human liver stem cells promotes liver regeneration in hepatectomized 
animal model [136, 148]. Being part of the secreted factors in the MSC-CM, 
we envisaged that exosomes could have a similar effect as reported which 
promotes liver regeneration in this context of DILI. To investigate the 
regenerative effect, few of the transcription factors and growth factors 
expression involved in different stages of cell cycle were examined using 
immunoblot assays using the harvested liver tissues. A small part of the 
harvested liver tissues were grinded and lysed. These lysates were then 
subjected to Western blot assay in order to detect the expression of HGF, pMet, 
NF-kB, pStat3, cyclin E1, cyclin D1 proteins. Densitometric analysis was 
carried out to quantify the expressions of each protein in the Western blot. As 
can be seen from Figure 14, exosomes treatment group in CCl4 showed 
significant upregulation of the hepatic regeneration gene expressions of NF-
B, cyclin D1 and cyclin E1 in respect to the vehicle treated control group. 
Since none of these proteins were found in the exosomes, we reasoned that the 
upregulation observed was an outcome of de novo synthesis from the host 
liver.  No significant upregulation was observed for HGF, pMet and pStat3 
gene expression. One of the possible explanations could be that the highly 
induced proteins were expressed at 24 hr after the introduction of CCl4, 
however the HGF, pMet and p Stat3 expressions could have been induced 
before or after the 24
th
 hr and thus the difference could not be detected during 
that time.   
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Figure 14 Effect of exosomes on hepatocyte proliferation after CCl4-
induced injury in mice. (A) Expression of cyclin E1, HGF, pMet, NF-B p65, 
cyclin D1 and phosphorylated Stat3 were determined by immunoblotting after 
24 hr of CCl4 administration with or without exosomes. n=6 per group 
(representative of 2 per group were shown in A); * p<0.05 versus of CCl4 
control. (B) The relative densities of all the proteins bands (n=6) were 









































    
3.2.6 Effect of exosomes on PCNA immunohistochemical staining (IHC) 
Following the significant increase of cyclin E1 and cyclin D1 protein 
expression in the Western blot assay, IHC was performed to cross validate the 
regenerative effect of exosomes using another cell proliferation marker, PCNA. 
Consistent with the previous results, the activation of proliferation marker was 
once again confirmed with the demonstration of higher staining intensity and 
amount of PCNA
+
 cells shown in the exosomes treatment group compared to 







    
 
 
Figure 15 Effect of exosomes on liver tissue proliferation after CCl4-
induced injury in mice. Livers were processed for IHC on PCNA to quantify 
hepatocyte proliferation after 24 hr of (A) CCl4 administration and (B) CCl4 
with exosomes treatment. Original magnification x 200; scale bar = 100 m. 





































Table 2 Summary of exosomes findings in vivo. 
 
In vivo 
Markers CCl4 CCl4 + exosomes 
Liver function test 
AST # * 





Promoter and transcription 
factors 
pMet - = 
p-Stat3 - = 
NF-kB - * 
Growth factor HGF - = 
Proliferation markers 
cyclin D1 - * 




  higher than control;  and  higher or lower than CCl4 alone; = no 
difference with CCl4 alone; # p<0.05 compared to control; symbol in red with 
* p<0.05 compared to CCl4 alone 
 
Putting these findings together, the administration of MSC-derived 
exosomes was found to mitigate CCl4-induced injury in vivo with active 
proliferation of hepatocytes, most clearly indicated with the expression of 
PCNA, cyclin D1 and cyclin E1. 
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3.3 INFLUENCE OF EXOSOMES AGAINST APAP- AND H2O2-INDUCED LIVER 
INJURY IN VITRO MODEL 
 
In vitro model was subsequently designed to validate the in vivo 
findings of exosomal protection and to gain further insights to its response 
towards different mechanisms of toxicity. APAP treatment represents liver 
injury model caused by both covalent modification of protein targets and 
oxidative stress mediated injury pathways [39]; while H2O2 treatment 
represents only the oxidative stress-induced liver injury pathway.  
 
 
3.3.1 Exosomes characterisation  
Three liver cell lines, TAMH, THLE-2 and HuH-7 cells were 
evaluated for cell viability to test the effect of exosomes. TAMH is an 
immortalized mouse hepatocyte line derived from transgenic MT42 male mice 
overexpressing TGF- [149] while THLE-2 is an immortalized primary 
human hepatocyte which expresses phenotypic characteristics of normal adult 
liver epithelial cells [140]. In contrast with the normal cell line, we also 
investigated the effect of exosomes in HuH-7, a well differentiated human 
hepatocarcinoma cell line. This comparison will help to strengthen the 
evidence of therapeutic effect of exosomes against different liver injury 
models in various liver cell types.  
Before the protective effect of exosomes was tested, exosomes 
cytotoxicity tests were performed in these three cell lines. A range of 
exosomes concentrations was tested in respective cell lines for 24 hr. In 
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TAMH cells, the exosomes did not cause significant decreased in cell viability 
up to 1 g/ml concentration (Figure 16A). On the other hand, the cell viability 
in THLE-2 cells remained consistent across different concentrations up to 10 
g/ml (Figure 16B). The same trend was observed in the Huh-7 cells where 
the lower concentrations of exosomes did not show any toxicity to the cells 
until it reached 10 g/ml (Figure 16C). Nevertheless, the concentrations 
which caused toxicity to the cells far exceeded the concentration which will be 
used in the following studies (i.e. 0.1 g/ml of exosomes) and hence, should 
not impact our study. This concentration was chosen because it demonstrated  
cardioprotective effect in a previous study [138].  
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Figure 16 Exosomes cytotoxicity tests. Experiments on cytotoxicity of 
exosomes were performed in (A) TAMH, (B) THLE-2 and (C) Huh-7 
hepatocytes. A range of different exosomes concentrations was added to 
respective cell lines and MTT were performed 24 hr later. Cell viability was 








    
3.3.2 Effect of exosomes on cell viability in APAP and H2O2-induced toxicity  
The three representative liver cell lines were then subjected to the two 
xenobiotics-induced injuries. Before the experiments, LC50 of APAP and H2O2 
in each cell line was determined by exposure to a range of the xenobiotics 
concentrations for a designated period of time. Both APAP and H2O2 
produced a concentration dependent loss of viability in all the three cell lines 
as evaluated by MTT assay. At 24 hr of incubation, the LC50 value of APAP 
was found to be 2 mM while LC50 for H2O2 was 350 M for TAMH cells 
(data not shown). The liver damage induced by APAP likely arise from the 
metabolism to reactive metabolite NAPQI, which is generated by phase I 
enzymes such as CYP2E1. Hence, APAP in THLE-2 and HuH-7 cells took 72 
hr to affect toxicity, compared to TAMH cells (24 hr) with higher metabolic 
capacity [150]. The LC50 value of APAP and H2O2 for THLE-2 cell was 3.5 
mM and 100 M respectively while for HuH-7 cell was 5 mM and 60 M 
respectively (data not shown). In the following experiments, these LC50 
concentrations were used as standard toxic concentrations in respective cell 
lines. 
To characterize the protective effect of exosomes on APAP and H2O2 
induced cytotoxicity in TAMH cells, experiments were conducted using 0.05 
and 0.1 g/ml of exosomes. Cytoprotection against APAP- and H2O2-induced 
liver injury in TAMH cells were clearly demonstrated (Figure 17A&B). In 
APAP-induced liver injury model, exosomes showed significant dose-
dependent increment in cell viability compared to non-treated group (Figure 
17A). However, in the H2O2 model, only a 0.1 g/ml of exosomes showed 
significant cytoprotection even though a dose-dependent trend was observed 
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(Figure 17B). The same concentration of exosomes seemed to demonstrate 
better protection against APAP- injury as compared to the H2O2-injury model. 
When cross-referenced and confirmed with THLE-2 and HuH-7, comparable 
results were observed. Treatment of 0.1 g/ml exosomes demonstrated 
significantly higher cell viability in both toxicant-induced liver injury models 
using THLE-2 (Figure 17C&D) and HuH-7 when compared with those 
without receiving exosomes. (Figure 17E&F).  
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Figure 17 Effect of exosomes in cell viability after APAP- and H2O2-
induced injury. Experiments were performed in TAMH (A-B), THLE-2 (C-D) 
and Huh-7 (E-F) hepatocytes. 0.05 g/ml and 0.1 g/ml of exosomes were 
added to respective concentrations of APAP (A, C, E) and H2O2 (B, D, F) and 
MTT were performed 24 or 72 hr later. Cell viability was normalized against 
vehicle control group and expressed in percentage. n=6 per group; *p<0.05 






    
 3.3.3 Effect of exosomes on gene regulation during priming phase of liver 
regeneration  
To investigate the effect of exosomes on inflammatory 
response/hepatic regeneration, mRNA expressions of inducible nitric oxide 
synthase (iNOS), cyclooxygenase-2 (COX-2), TNF-α, IL-6 and macrophage 
inflammatory protein 2-alpha (MIP-2) which are the key genes involved in the 
inflammation as well as liver regeneration of cytokine-dependent pathway 
were measured. By determining the modulation of these early priming 
cytokines expression, exosomal mechanism of cytoprotection could be 
elucidated. Hence, cell growth was firstly arrested by culturing in low glucose 
DMEM/F12 medium for 2 days. Then, treatment with APAP or H2O2 was 
introduced, either with or without MSC-exosomes. Finally, gene expression 
levels of the priming factors were measured post-24 hr of these treatments. As 
shown in Figure 18A, APAP treatment alone caused elevated expression in 
TNF-, COX-2 and IL-6 by 1.4-, 1.8- and 3.2-fold respectively. No 
statistically significant elevation was observed for iNOS and MIP-2. However, 
0.1 g/ml of exosomes-treated group were observed to have elevated mRNA 
expression of TNF-, IL-6, iNOS, COX-2 and MIP-2, as compared to the 
APAP untreated group. In APAP-injury model, MIP-2 demonstrated highest 
elevation with 3.7-fold, followed by 2.4-fold in COX-2 and 2-fold in iNOS. 
On other hand, H2O2 challenge remarkably up-regulated the expressions of 
COX-2, IL-6 and MIP-2 genes but down-regulated iNOS and TNF-. The 
slight difference in the expression trend between APAP and H2O2 could be due 
to the injury level caused by different mechanism pathways. As shown in 
Figure 18B, the elevation trend differed slightly in the H2O2-injury model 
A 
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whereby the same amount of exosomes was found to increase iNOS 
expression the most significantly, by approximately 2.9-fold, followed by 2.0-
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Figure 18 qRT-PCR analysis of iNOS, TNF-, COX-2, IL-6, IL-10 and 
MIP-2 expression. Liver inflammatory responses/regeneration-cytokine 
expressions in TAMH cells treated with or without exosomes concurrently in 
(A) 2 mM APAP or (B) 350 M H2O2, for 24 hr. All the expressions were 
normalized against GAPDH expression of the same sample and presented as 
fold-increase over the controls. # p<0.05 for APAP or H2O2 versus of vehicle 

























    
3.3.4 Effect of exosomes on the induction of transcription factors during the 
G1 phase of cell cycle  
Based on the observed elevation of TNF- and IL-6 with exosomal 
treatment, the downstream effect of NF-B and Stat3 transcription factors 
activation in G1 phase of cell cycle were explored. These activations support 
the propagation of proliferative signals during liver regeneration [151]. The 
activation of these factors was investigated by immunoblotting of NF-B (p65 
and p50) and phospho-Stat3 (Tyr705) after treatment of exosomes in both 
xenobiotics-induced hepatocytes injury models. In the absence of exosomes 
treatment, APAP- and H2O2-treated cells exhibited low basal level of NF-B 
and phospho-Stat3 activity (Figure 19 lane 2 & 5, respectively). With 
exosomal treatment, NF-B (both p50 and p65) and phospho-Stat3 activities 
were restored to the normal expression level in APAP-induced injury (Figure 
19 lane 3 & 4). Interestingly, higher levels of expressions of the two proteins 










Figure 19 Effect of exosomes in G1 phase of cell cycle after APAP- or 
H2O2-induced injury in TAMH hepatocytes. Expressions of NF-B (p65 
and p50) and phosphorylated Stat3 were determined by immunoblotting after 
24 hr treatment in APAP- or H2O2-injury models. Blot shown here was 
representative from a number of experiments, n=3. In densitometry for this 
representative blot, of NF-B and phosphorylated Stat3 bands were 
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3.3.5 Effect of exosomes on cell proliferation markers during G1 and S 
phase of cell cycle   
Following the observed restoration of NF-B and Stat3 signaling with 
exosomal treatment, the search for biochemical evidence of active cell cycling 
by monitoring cyclin D1 and PCNA were pursued. Exosomes treatment 
increased expression of PCNA during APAP- and H2O2-injury while only 
cyclin D1 with 0.1 g/ml exosomes was highly expressed in APAP-injury 
(Figure 20). This finding is in consistent with our earlier results which 
demonstrated that MSC-derived exosomes promoted hepatocytes regeneration 
and proliferation during acute injury. Moreover, it has been shown that 
exosomes alone does not induce any proliferation [152]. 
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Figure 20 Effect of exosomes in cell proliferation after APAP- or H2O2-
induced injury in TAMH hepatocytes. (A) Expressions of cyclin D1 and 
PCNA were determined by immunoblotting after 24 hr treatment in APAP- or 
H2O2-injury models. Blot shown here was representative from a number of 
experiments, n=3. (B) In densitometry for this representative blot, the relative 







    
3.3.6 Effect of exosomes on caspase 3 activity and apoptotic gene Bcl-xL  
Besides the role as a mitogenic transducer, Stat3 induction is also 
indicative of early response towards promotion of anti-apoptotic activity. Stat3 
could suppress Fas-mediated liver injury either by a redox-dependent 
mechanism through expressing anti-apoptotic genes such as Bcl-xL, Bcl-2 
[153], or by a redox-independent mechanism through expressing Ref-1 [154] 
or anti-oxidative gene, manganese superoxide dismutase (MnSOD) [155]. To 
further determine if the anti-apoptotic effect was due to the upregulation of p-
Stat3, caspase 3/7 activities were measured in this study. Both toxicant-only 
treatments resulted in significant increment of active caspase 3 and reduction 
of anti-apoptotic gene, Bcl-xL as compared to the control (Figure 21A & B). 
Similar to the favorable outcomes in cell viability, in APAP-injury model, 
exosomes treatment significantly suppressed the activity of caspase 3. This 
suppression was not observed in the H2O2-injury model. As for Bcl-xL, 
treatment of exosomes seemed to reverse the suppression observed in toxicant-
only treatment. With higher exosomes concentrations, further increase in 
expression was demonstrated in both APAP- and H2O2- induced injury models 
(Figure 21B lanes 4 & 7). Apart from apoptotic cells, necrotic cells were 
detected in FACS using PI-stainingin both toxicants induced injury models 
(data not shown), but the effect of exosomes on necrosis was not explicitly 











Figure 21 Effect of exosomes on anti-apoptosis in APAP- or H2O2-induced 
injury in TAMH hepatocytes. (A) Caspase 3/7 was measured after 24 hr 
treatment of exosomes in APAP- or H2O2-injury, n=3; # p<0.05 versus of 
vehicle control; *p<0.05 versus APAP or H2O2 non-exosomes treatment group. 
(B) Expressions of Bcl-xL were determined by immunoblotting after 24 hr 
treatment in APAP- or H2O2-injury model. Blot shown here was representative 
from a number of experiments, n=3. (C) The relative intensities of Bcl-xL 
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3.3.7 Effect of exosomes on anti-oxidant gene activity  
To further assess the anti-apoptotic effect of exosomes mediated 
through the anti-oxidative pathway, mRNA expression of several major 
enzymatic antioxidants which are commonly involved in the oxidative 
pathway, namely HO-1, Gpx4, GSR and MnSOD were measured. In both 
injury models, only HO-1 mRNA expression was highly induced at 24 hr time 
point of each toxicant treatment while Gpx4, GSR and MnSOD genes 
remained relatively unchanged as compared to control in APAP. Gpx4 and 
MnSOD were slightly upregulated after H2O2 treatment. However, there was 
no significant concerted effect observed among the genes measured between 
the exosomes and non-exosomes treated groups (Figure 22A & B). Therefore, 
exosomes do not regulate the anti-oxidative pathway in DILI. 
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Figure 22 qRT-PCR analysis of HO-1, Gpx-4, GSR and MnSOD 
expressions. Liver stress/defense-related genes expression in TAMH cells 
treated with or without exosomes concurrently in (A) 2 mM APAP or (B) 350 
M H2O2, for 24 hr. All the expressions were normalized against GAPDH 
expression of the same sample and presented as fold-increase over the controls. 
# p<0.05 for APAP or H2O2 versus of vehicle control; *p<0.05 versus APAP 










Table 3 Summary of exosomes findings in vitro in TAMH cells. 






Cell viability MTT # * # * 
Priming phase 
genes 
iNOS # * #  
TNF- # *   
COX-2 # * # * 
IL-6 # * # * 




NF-kB     
p-Stat3     
G1 & S phase 
proliferation 
markers 
Cyclin D1     




Caspase 3 # * #  
Bcl-xL     
Anti-oxidative 
genes 
HO-1 #  #  
Gpx4 = = # * 
GSR = = = * 
MnSOD = = #  
 and  higher or lower than control or  APAP or H2O2 alone; = no difference 
with CCl4 alone; # p<0.05 compared to control; symbol in red with * p<0.05 




    
The in vitro results demonstrated higher cell viability after the 
treatment of exosomes in both toxicity models. Along with that, the exosomes 
also caused the induction of priming phase genes which induced quiescent 
cells to reenter cell cycle. This results in higher expression of G1 phase 
transcription factors as well as cell proliferation markers. Exosomes were also 
able to protect the injured cells through regulating the anti-apoptosis pathway 
which involves the Bcl-xL as well as caspase 3/7 expressions but not through 
the modulation of oxidative stress (Table 3).  
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3.4 DISCUSSION 
 
We began this part of the study with the hypothesis that the size 
purified subset of exosomes derived from MSC-CM can play a role in 
mitigating xenobiotics-induced liver injury. As a proof of concept, we 
explored such an effect using a classical model of in vivo liver toxicity, i.e., 
CCl4 induced hepatic injury in mouse. We further considered the selectivity 
and the mechanism of the anticipated protection using in vitro models of well-
defined mechanism of toxicity- APAP and H2O2. Accordingly, our 
experiments have demonstrated that the MSC-derived exosomes accelerated in 
vivo liver regeneration in CCl4 injured mice. In addition, we have found that 
exosomes consistently caused increased in cell viability after injuries arising 
from both APAP- and H2O2.  
In vivo study, the administration of MSC-derived exosomes was found 
to mitigate CCl4 induced injury mice with active proliferation of hepatocytes, 
most clearly indicated with the expressions of PCNA, cyclin D1 and cyclin E. 
These proliferation effects were in line with the in vitro findings where 
exosomes were able to sustain higher cell viability of hepatocytes after both 
injuries with cytototoxic doses of APAP and H2O2. We qualified the 
regenerative potential of these exosomes by investigating the biochemical 
machinery behind the effect, beginning from the priming phase that triggers 
growth arrested injured cells to re-enter cell cycle (see Figure 23).  
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Figure 23 Cell cycle with the genes and proteins involved in each stage. 
 
 
The liver's repair mechanisms are complex and likely involve immune, 
inflammatory, and regenerative factors. Inflammation is a critical part of the 
host response to injury and is intimately tied to tissue repair and wound 
healing. To elucidate the molecular pathway of the inflammatory/regenerative 
response, we used the well-established two-third partial hepatectomy (PH) 
model system to guide the investigation. Since PH is a very different type of 
liver model as compared to xenobioic-induced injury, we cannot assume that 
the residual liver cells may still be competent for regeneration. Therefore in 
this study, we investigated each of these biochemical components in greater 
details. Studies utilizing PH models have implicated that cytokines, IL-6 [156] 
and TNF- [157] are prominent in initiating liver regeneration and mediating 




Growth factors:  
HGF, EGF, TGF- 





    
and Stat3 [159], which govern the expression of genes controlling hepatocytes 
viability and proliferation. In particular, TNF- and IL-6 are important for 
early signaling pathways that lead to regeneration [156, 160]. Studies showed 
that deficiency in TNF- type I receptor is associated with impaired DNA and 
IL-6 synthesis after PH [83]. Hence, in addition to initiating growth-related 
signaling in hepatocytes, TNF- is also a critical mediator in inducing IL-6 
post PH. IL-6 is required to stimulate acute phase protein synthesis by 
hepatocytes as part of the overall inflammatory response [161]. The 
importance of IL-6 on the regenerative response was demonstrated when IL-
6
−/−
 mice developed defective regeneration after PH [84]. Therefore in our 
qRT-PCR experiments, we examined similar markers and observed that higher 
exosomes concentrations were associated with higher IL-6 and TNF-
expression levels, which led to higher cell viability. However, IL-6 
expression was more pronounced than TNF- expression, especially in H2O2 
model treated with 0.1 g/ml exosomes (Figure 18).  
Aside from cytokines and transcription factors, iNOS, a protein was 
demonstrated to mediate the formation of NO [79, 162] and COX-2, which 
catalyzes the rate-limiting step in the synthesis of prostaglandins (PGs) that 
control the regenerative process. The iNOS is released in the liver at 4-6 hr 
following PH [162]. In iNOS knockout animal model, the significant 
increment in hepatocytes apoptosis after PH indicated that iNOS could be 
involved in anti-apoptosis process during liver regeneration [163]. This 
finding is consistent with another study where the liver regeneration in iNOS 
knockout mice was delayed after PH, and with higher serum ALT levels 
compared to the control mice [164]. Accordingly, we observed similar 
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phenomena in our cell viability studies. APAP or H2O2 treatment caused 
drastic depletion in iNOS mRNA expression, which could be associated with 
the low cell viability. In the exosomes treatment group, higher cell viability 
was observed which could be due to the restoration of iNOS expression. It is 
believed that NO plays an important role in liver homeostasis and disease, be 
it beneficial or detrimental. Despite the prevention of apoptosis function, other 
studies have also showed that release of NO contributes to warm 
ischemia/reperfusion (I/R) injury [165, 166] and exacerbate APAP 
hepatotoxicity injury [167, 168]. These conflicting results may be attributable 
to the different types of cells used, source and amount of NO production, 
abundance of ROS, the extent of the underlying injury and the cellular redox 
status of liver.  
Expression of COX-2 and its product, PGs have been demonstrated in 
the remnant liver 16 hr after PH [169] and are important for the early step in 
liver regeneration [170]. In contrast to the common suggestion that COX-2 is a 
pro-inflammatory/toxicant pathway, our results demonstrated that expression 
of COX-2 increased after exosomes treatment alongside improved cell 
viability. Indeed, inhibition of COX-2 activity has been found to impede cell 
proliferation after PH [171]. The rate of cell proliferation post PH signifies 
cell regeneration whereby the faster the rate, the better the regeneration is. In 
accordance to this, mice deficient in COX-2 have showed increased 
susceptibility to APAP-induced liver injury [172]. Moreover, Mayoral et al., 
had demonstrated that COX-2-dependent PGs protects against acute liver 
injury through anti-apoptotic effect by accelerating early stages of hepatocytes 
proliferation [173]. Hence, as anticipated, simultaneous suppression of iNOS 
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and COX-2 in the study by Zeini et al., had perturbed the balance between cell 
regeneration and apoptosis, resulting in massive hepatocytes death [174].  
Post PH elevation of CXC chemokines has been observed in a recent 
study and is linked to liver regeneration [175]. Treatment of MIP-2, a member 
of the CXC family was found to enhance hepatocytes proliferation in a similar 
mouse model [176]. Interestingly, this hepatoprotective effect of MIP-2 
happens only at low concentration while high concentrations will bring about 
significant toxicity [177]. Our findings demonstrated that MIP-2 mRNA 
expression increased 2- to 3-fold after exosomes treatment. This increment 
translated into improved cell viability as compared to those without exosomes-
treatment. This finding corroborated reported studies where 3- to 5- fold 
increment in MIP-2 expression after PH [175] is beneficial to the liver 
regeneration while 25- to 50- fold increment after I/R is detrimental [177]. 
Taken together, our results demonstrated the increased in expressions of all 
these priming phase factors after exosomes treatment alongside improved cell 
viability. Despite the use of a monoculture system comprising exclusively of 
hepatocytes, we were able to pick up signatures of cytokine perturbations, 
consistent with other similar liver cell line studies reported in literature [178, 
179]. 
TNF- initiates liver regeneration by activating the NF-B and IL6-
dependent pathways which involve Stat3 transcription factor [180] in the G1 
phase. In the current investigation, Western blot demonstrated injured 
hepatocytes with exosomes treatment markedly increased the expression of 
NF-B and Stat3 transcription factors. The IL-6/Stat3 pathway subsequently 
initiates cell cycle progression from G1 to S phase, as shown in the 
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upregulation of cyclin D1 and PCNA after exosomes treatment. In line with 
the priming factors and transcription factors, these up-regulated genes and 
protein expressions collectively support a restoration of overall cell viability, 
suggesting that the exosomes therapy likely mediates the liver repair from 
acute liver injury through induction of liver regeneration in the hepatocytes. 
Apart from that, the NF-B and Stat3 transcription factors are also involved in 
the expression of acute phase proteins which act to restore the liver 
homeostasis [76]. In the process of characterizing the mode of action of 
exosomes, we were aware of a possible differential response towards the type 
of cellular injury invoked by the toxicants. Hence, two mechanistically distinct 
injury models were investigated. APAP is a well-studied hepatotoxicant that 
mediates the liver injury pathway principally through generation of its reactive 
metabolite, NAPQI and subsequent binding to hepatic proteins [181], while 
H2O2 solely mediates liver injury through the oxidative stress pathway. 
However, a common effect observed in both injuries is the manifestation of 
mitochondrial dysfunction leading to apoptosis [33, 182]. Since the exosomes 
demonstrated protective or injury repair effect in both models albeit to a 
different extent, a possible effect in mitigating oxidative stress was 
investigated. Previously, Stat3 was also shown to regulate mitochondrial Bcl-
xL and MnSOD expression in inhibiting caspase 3 during apoptosis [153, 155]. 
Our results demonstrated that the Bcl-xL expression increased with higher 
expression of Stat3 after the treatment of exosomes while caspase 3/7 
expression was significantly decreased in the APAP-injury group treated with 
exosomes. This suggests that exosomes were able to alleviate some 
mitochondrial dysfunction as part of its plethora of protective mechanisms in 
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the anti-apoptosis pathway. However, exosomes did not demonstrate a role in 
regulating anti-oxidative genes, and hence did not mitigate injury via 
modulation of oxidative stress. These suggest that exosomes primarily assert 
anti-apoptotic, proliferative and regenerative hepatic responses to liver 
damage (Figure 24). 
Despite the promising effects exosomes displayed, our experimental 
results are less conclusive about its role in modulating the mitochondria ATP 
and oxidative stress as the triggers of APAP and H2O2-indcued injury. This 
outcome is not surprising. It has been claimed that the exosomes enhanced 
myocardial viability after MI/R injury through increasing the ATP and NADH 
levels, decreasing the oxidative stress while activating the PI3K/Akt pathway 
[183]. During the ex vivo MI/R injury, exosomes were introduced 5 min prior 
to reperfusion and the oxidative stress injury usually only happen after 5 
minutes and aggravates after 30 minutes of reperfusion, it is more likely that 
the exosomes prevented the MI/R injury; thus less depletion in ATP and 
NADH levels and elevation in oxidative stress were detected due to less injury. 
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Figure 24 Proposed summary of exosomes protection mechanisms against 
DILI through anti-apoptotic and regeneration pathways. 
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To be able to translate these mechanistic insights into potential therapy, 
a necessary follow-up work would be to determine the hepatoprotective  or 
hepatoregenerative components within the exosomes. That said, existing 
proteomics studies on the contents of exosomes has given us some clues and 
starting points for investigation. Exosomes has been shown to contain 
biologically active proteins, lipids, mRNA and miRNA [184-186] (See 
supplementary table 1). Lai et al., has profiled a total of 857 proteins in the 
exosomes using mass spectrometry and antibody array [187]. Here, few of the 
prominent proteins which are potential components involved in the liver 
regeneration process were identified. Among them, IL6ST/gp130, 
TNFRSF1A/TNFR1 and CXCL2/MIP-2 proteins were found to be associated 
with the priming factors during liver regeneration. IL6ST plays an important 
role in mediating the IL-6/Stat3 pathway which initiates the hepatocytes 
protection [188-190]. Likewise, CXCL2/MIP-2 enhances hepatocytes 
proliferation through upregulating Stat3 expression during the process of 
recovery from injury [176, 191, 192]. These proteinaceous contents could be 
released from the exosomes intra-hepatically, triggering the higher expressions 
of IL-6, TNF- and MIP-2 after treatment as shown in our results. Apart from 
the priming factors, HGF and HGFR proteins which are one of the most potent 
stimulators of hepatocytes growth in the liver regeneration [193, 194] can also 
be found in the exosomes. These proteins might be working synergistically 
with the priming factors in accelerating and promoting liver regeneration, 
leading to a restoration of homeostasis. However, it remains to be determined 
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whether miRNAs or other mRNAs found in the exosomes may have any 
impact on the proliferation effect of the hepatocytes. 
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3.5 CONCLUSION 
 
In conclusion, exosomes treatment demonstrated substantial liver 
recovery after several toxicants-induced injuries. It is mediating this effect 
likely through maintaining liver homeostasis which primarily includes 
inducing hepatocyte regeneration. This treatment may present a novel 
adjunctive therapy in drug induced liver toxicity, in lieu of the limited 
availability of the conventional liver transplants. Since human MSC-exosomes 
do not contain any major histocompatibility complex (MHC) class I or II 
proteins, and their infusion into non-immune-compatible animals does not 
induce overt immune reactions [138, 139], we envisage them to be suitable for 
use in allogenic recipients. Furthermore, its attractiveness also lies largely on 
its non-cell based system while availing an abundant and reproducible supply. 
This work supports further investigation to clarify the exact mechanism of 













    
4.1 INTRODUCTION  
 
Preceding work described in Chapter 3 has captured the promising 
effects of MSC-derived exosomes in DILI, featuring a more dominant role in 
hepatoregeneration. While this outcome provides avenues for further 
development, the conspicuous absence of a mechanism to block the initiating 
injury caused us to also consider alternative routes. As described in Chapter 1, 
we therefore proposed a cytoprotective approach using isoform-specific 
Vitamin E. Specifically, we consider that -T3 has the potential to protect 
from xenobiotics-induced injury by exerting its antioxidant activity. However, 
its antioxidant and other uncharacterized effects have yet to be explored in the 
DILI model. Thus this study is set to examine the hepatoprotective or 
hepatoregenerative effect of -T3 against APAP- and H2O2-induced liver 





    
4.2 CHARACTERIZATION OF TOCOTRIENOL ANALOGS IN TAMH CELLS 
 
Before any assessment on the Vitamin E analogs was conducted, the 
characterization of T3 analogs and -TP was performed in TAMH cells. 
Firstly, the cytotoxicity of each analog was determined in order to ascertain 
the non-toxic dosage which will not jeopardize cell viability. This is followed 
by characterizing cellular uptake of each analog in TAMH cells, given the 
notion that uptake in a different cell line may differ, and each analog may have 
different uptake rate and amount accumulated in the cells. In addition, 
determining cellular uptake of such analogs is particularly relevant because 
this class of compound is characterized by poor solubility, and the 
incorporation into the liposomal membranes depends on which liquid phase 





    
4.2.1 Cytotoxicity of T3 analogs in TAMH cells 
The cytotoxicity test was performed at the following range of 
concentrations 0 M, 10 M, 25 M, 50 M and 100 M. The analogs were 
diluted from a neat ethanol stock by 1000 fold into working concentrations. 
After dilution in the medium, it is important to vortex the solution for at least 
30 s to 1 min in order to ensure a homogenous size and distribution of the 
analogs in the medium. The TAMH cells on a 96 well plate seeded overnight 
for 24 hr were treated with reconstituted analogs with 0.1 % of ethanol as the 
background for vehicle control group. Subsequently, MTT was performed to 
obtain total percentage of viable cells as described previously (Chapter 2). 
Figure 25 showed that -TP and -T3 were not toxic at up to a concentration 
of 100 M and the cell viability was maintained above 80%. On the contrary, 
significant drop in cell viability was observed in -T3 and -T3 even at the 
lowest concentration of 10 M. According to our results, 25 M and 50 M of 
-T3 and -T3 exhibit the highest cytotoxicity effect in TAMH cells which 
kills around 40% of the viable cells. However the trend seemed to be reversed 
when the concentration increased from 50 M to 100 M where cell viability 
restored slightly.  
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Figure 25 Vitamin E cytotoxicity test in TAMH hepatocytes. Experiments 
on the cytotoxicity of Vitamin E analogs were performed in TAMH 
hepatocytes. 0 M, 10 M, 25 M, 50 M and 100 M of each analog were 
added and MTT were performed 24 hr later. Cell viability was normalized 

































    
4.2.2 Cellular uptake of different concentration of T3 analogs in TAMH 
cells 
Apart from the cytotoxicity characterization, determining the cellular 
uptake of Vitamin E analogs was crucial to subsequent investigation of the 
biological effectiveness of each analog in the cells. Although many of the 
studies reported that at equimolar -T3 and -TP, -T3 is more potent in 
terms of its antioxidant effect than -TP against different injuries, Saito et al., 
reported that cells containing similar amounts of -T3 and -TP showed 
comparable resistance against oxidative stress caused by peroxides [195]. That 
said, an inference from this report is that the apparently higher cytoprotective 
effect of -T3 than -TP could be ascribed to its higher cellular uptake. For 
this reason, the characterization of cellular uptake is important in providing a 
basis on the comparison effect of each analog.  
 A series of 5 M 10 M, 25 M, 50 M and 100 M of each analog 
was added to TAMH cells (seeded overnight) for 24 hr. The harvested cell 
pellets were washed twice with PBS to remove traces of analogs which may 
adhere on the surface of the cells before lysis. The analogs were then extracted 
from each cell lysates and subjected to HPLC separation and quantification 
using PMC, an -TP derivative as internal control. The cellular uptake was 
expressed by taking the total amount of analog absorbed divided by the total 
protein content, g/g. At the lowest concentration of 5 M, the -T3 and -
T3 cellular uptake were similar while -T3 held the highest uptake among the 
analogs, resulting in a 1.6 and 3-fold higher uptake than -TP respectively 
(Figure 26). The uptake of -TP remained unchanged across all the 
concentrations after 24 hr while the other T3 analogs increased with the 
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concentrations. Again, -T3 remained the highest uptake while uptake of -T3 
exceeded that of -T3 after 25 M which resulted in the second highest 
uptake after -T3 at 100 M. The increase in cellular uptake is not directly 
proportional to the increase in concentration. This dose dependent study of 
cellular uptake of analogs revealed the enhanced incorporation of -T3, -T3 
and -T3 compared to that of -TP after incubation for 24 hr across all the 
concentrations.  
This results hold for the monolayer culture where the uptake of -TP is 
the lowest among the analogs tested. However, this is not the case for animal 
study where these T3 analogs concentrations in various tissues in animal study 
were found to be extremely low compared to -TP [196]. Thus, this 
strengthens the importance of characterizing the cellular uptake in every 
model before further tests were carried out, and further informs that 
































































Figure 26 Cellular uptake of -TP, -T3, -T3 and -T3 in TAMH 
hepatocytes. The cells were cultured in DMEM/F12 medium with each 
analog at the indicated concentrations for 24 hr and the cellular Vitamin E 
analog content was measured using an HPLC system. Mean values of cellular 


























































































































































































































Figure 27 Summary on the cytotoxicity and cellular uptake of -TP, -T3, 
-T3 and -T3 in TAMH hepatocytes. The cytotoxicity and cellular uptake 







    
 
Comparing the cytotoxicity results and the cellular uptake, -TP 
cytotoxicity remained unchanged and this could be due to the low level of 
unchanged cellular uptake even up to 100 M (Figure 27). Nevertheless, 100 
M of -T3 with 3.4 fold of cellular uptake higher than the -TP did not 
affect its cytotoxicity in TAMH cells. However, by comparing -T3 to the 
similar uptake of -T3 at the starting concentration of 10 M and 25 M, the 
reduction in cell viability could be attributed to its structural or inherent 
toxicity rather than the total amount in the cells which caused the cytotoxicity. 
Apart from that, the highest cellular uptake at 100 M of -T3 resulted in 
similar cell viability in 10 M, although there was a 3.3-fold increased in the 
uptake. On the other hand, the cell viability decreased with increase in cellular 
uptake of -T3 but plateau from the concentration of 25 M onwards which 
resulted in 60% of cell viability even up to 100 M with 2-fold increased in 
the total -T3 uptake. 
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4.3 EFFECT OF T3 ANALOGS AGAINST APAP- AND H2O2-INDUCED IN LIVER 
INJURY IN VITRO 
 
We employed the same injury models as conducted for the exosomes 
treatment under Chapter 3 using TAMH cells to assess the effect of T3 
analogs in cell viability assay as well as other in vitro experiments. The LD50 
concentration for APAP and H2O2 used were the same as optimized previously 
in the same cell line. The effects of T3 analogs were then compared with -TP, 
where the anti-oxidative activities were well characterized. 
 
 
4.3.1 Effect of T3 analogs on APAP and H2O2-induced on cell death in 
TAMH cells  
a) Concurrent treatment 
The effect of T3 analogs and -TP were investigated against both the 
APAP and H2O2 injury models using MTT assay. In the first experiment, 
cultures were first exposed concomitantly to APAP or H2O2 in the presence or 
absence of T3 analogs or -TP (10 – 100 M) for 24 hr. In the APAP toxicity 
model, -TP and -T3 demonstrated dose dependent suppression of APAP-
induced toxicity, with minimal effective concentration of 25 M and 10 M 
respectively (Figure 28A). None of the -T3 or T3 was effective in 
protecting APAP injury across the concentrations tested. The overall 
percentage recovery in -T3 was shown to be higher as compared to -TP. 
Similar trend was observed with the H2O2 toxicity model, where 
concomitant administration of -TP and α-T3 (10 - 100 M) with H2O2 for 24 
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hr inhibited H2O2-induced cytotoxicity in a concentration dependent manner. 
The protective effect reached statistical significance from a concentration of 
10 M onwards (Figure 28B). In contrast, none of the γ-T3 concentration (10–
100 M) modified the cytotoxicity of H2O2. 50 and 100 M of δ-T3 managed 
to exert though significant, mild protection against H2O2. Again, -T3 




    
   
 
Figure 28 Concurrent effects of -TP, -T3, -T3 and -T3 in cell viability 
after APAP- and H2O2-induced injury in TAMH hepatocytes. 0 M, 10 
M, 25 M, 50 M and 100 M of each Vitamin E analog were added to 
respective concentration of APAP (A) and H2O2 (B) concurrently and MTT 
were performed 24 hr later. Cell viability was normalized against vehicle 
control group and expressed in percentage. n=6 per group; * p<0.05 versus 
APAP or H2O2 at 0 M treatment group.   
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b) Pre-treatment 
The pre-treatment model is set up to rule out the possibilities of some 
confounding factors in the concurrent treatment model. In the concurrent 
treatment, the major concern is whether the antioxidants, -TP or -T3 
reacted directly with or quenched the H2O2 in the medium mixture before they 
were taken into the cells. By carrying out the pre-treatment model, we can 
ascertain that they did not react in the mixture and the protective effects 
observed were an outcome of a cell-based mechanism. Pre-treatment in vitro 
model was also performed to investigate the effect of each analog against 
APAP and H2O2-injury model. This was performed by incubating the seeded 
cells with different concentrations of each analog for 24 hr, followed by APAP 
or H2O2 incubation for another 24 hr after a complete wash of the cells with 
PBS to remove traces of the analogs on cell surface. MTT was carried out 
after that to obtain total viable cells after the injuries. Based on the results as 
shown in Figure 29A, both -TP and -T3 demonstrated significant higher 
cell viability from concentration of 25 M and above. In the concurrent 
treatment experiments, -T3 and - T3 did not showed any protective effect 
against APAP. On the other hand, the effect of -TP and -T3 against H2O2 
on cell viability were found to be more significant where the effective dose 
were observed starting from 10 M (Figure 29B). Similarly with APAP, -T3 
and -T3 resulted in lower cell viability compared to the toxicant with no -
T3/-T3 treatment. Apart from that, the difference in protective effect 
observed with the concurrent treatment could be affected by the analog’s 
uptake rate and the total amount accumulated in the cells. The faster uptake 
may result in higher amount of analog in the cells during the first few critical 
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hours of injury. Thus the analog may result in higher protection and efficiency 
against the injuries. This might be crucial timing for the rescue to happen. By 
ruling out these confounding factors, the only difference is the total amount of 
each analog in cells after the 24 hr of uptake. Thus, the results from pre-
treatment differ slightly from the concurrent treatment. 
Overall, both -T3 and -T3 did not exhibit any consistent 
cytoprotective effect in both concurrent and pre-treatment assay at a 
concentration up to 100 M. This could be due to the over-riding toxicity as 
demonstrated in the cytotoxicity study, thereby masking any potential 
cytoprotective effect they may exert. For this reason, lower concentration 
range for -T3 and -T3 was used to carry out the same experiments as 




    
   
Figure 29 Pre-treatment effects of -TP, -T3, -T3 and -T3 in cell 
viability after APAP- and H2O2-induced injury in TAMH hepatocytes. 0 
M, 10 M, 25 M, 50 M and 100 M of each Vitamin E analog were firstly 
added into TAMH cells for 24 hr, followed by the toxicant treatment of APAP 
(A) and H2O2 (B) and MTT were performed 24 hr later. Cell viability was 
normalized against vehicle control group and expressed in percentage. n=6 per 














































































    
4.3.2 Effect of lower dosage of -T3 and -T3 against APAP and H2O2-
induced injury on cell viability in TAMH cells  
Accordingly, a series of lower dosage of -T3 and -T3 were tested on 
the cytotoxicity in TAMH cells. Figure 30A&B showed that these series of 
concentrations were not toxic to the cells where the cells were maintained at 




Figure 30 Lower dosage of -T3 and -T3 cytotoxicity test in TAMH 
hepatocytes. (A) Experiments on the cytotoxicity of -T3 and -T3 at lower 
dosage were performed in TAMH hepatocytes. 0 M, 0.5 M, 1.0 M, 2.5 
M and 5 M of each analog were added and MTT were performed 24 hr later. 
(B) Combination of cytotoxicity of -T3 and -T3 from lowest to highest 
dosage in TAMH hepatocytes. Cell viability was normalized against vehicle 


























































    
Next, these lower dosages of -T3 and -T3 were treated concurrently 
with APAP or H2O2. Referring to Figure 31A&B, cell viability improved 
significantly only with the treatment of -T3 but not in -T3, at a 
concentration of 5 M and 2.5 M to 5 M respectively for APAP and H2O2 
models. On the contrary, none of the lower concentration of -T3 or -T3 
demonstrated protective effect against APAP and H2O2 in the pre-treatment 
models (Figure 32A&B). 5 M of -T3 pre-treatment in APAP resulted in 
significantly lower cell viability. Since there was no protective effect found 
even at a lower dosage of -T3 and -T3, the following experiments were 
focused on the more promising effects of -T3 and its mechanism of action in 










Figure 31 Effects of lower dosage of -T3 and -T3 in cell viability after 
APAP- and H2O2-induced injury in TAMH hepatocytes. 0 M, 10 M, 25 
M, 50 M and 100 M of each analog were added to respective 
concentration of APAP (A) and H2O2 (B) concurrently and MTT were 
performed 24 hr later. Cell viability was normalized against vehicle control 
group and expressed in percentage. n=6 per group; * p<0.05 versus APAP or 


































































Figure 32 Effects of -T3 and -T3 in cell viability after APAP- and H2O2-
induced injury in TAMH hepatocytes. 0 M, 10 M, 25 M, 50 M and 
100 M of each analog were firstly added into TAMH cells for 24 hr, 
followed by the toxicant treatment of APAP (A) and H2O2 (B) and MTT were 
performed 24 hr later. Cell viability was normalized against vehicle control 
group and expressed in percentage. n=6 per group; * p<0.05 versus APAP or 




























































    
4.3.3 Effect of -TP and -T3 on GSH activity  
After confirming the cytoprotective effect of -TP and -T3, two 
doses of these analogs: a lower dose at 10 M and a higher dose at 50 M, 
were used to execute the following experiments. Firstly, in order to further 
investigate the underlying mechanisms of APAP and H2O2 toxicity and the 
antioxidant action of these analogs, cellular GSH levels were determined. 
Continuous oxidative stress from these reactions will thus give rise to 
depletion of the intracellular GSH content and this can exacerbate the cellular 
injury into initiation of the mitochondria-dependent apoptosis pathway. 
Similar to the results as reported, Figure 33A&B demonstrated significant 
depletion of intracellular GSH after 24 hr incubation of APAP or H2O2. The 
decreased of GSH in APAP was not inhibited by any cytoprotective 
concentration of -TP or -T3 (Figure 33A). However 10 M of -TP and 
both concentrations of -T3 exhibit antioxidant activity, most likely by 
reacting with the ROS or the electrophiles, maintaining its intracellular GSH 







    
 
 
Figure 33 Effects of -TP and -T3 in GSH after APAP- and H2O2-
induced injury in TAMH hepatocytes. 0 M, 10 M and 50 M of each 
analog were added into TAMH cells concurrently with APAP (A) and H2O2 (B) 
and cellular GSH levels were performed 24 hr later. n=3 per group; # p<0.05 
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4.3.4 Effect of -TP and -T3 on intracellular ROS  
In normal cells, the intracellular ROS level is usually maintained at a 
stable state. However, this redox equilibrium is altered when the cells were 
incubated with toxicants like APAP and H2O2, which produce ROS or 
attenuate antioxidant capacity. After 24 hr incubation of these toxicants, the 
intracellular ROS level was determined by fluorescent probe CM-H2DCFDA 
and normalized against total number of cells. The results revealed that both 
APAP and H2O2-induced death of TAMH hepatocytes was preceded by a 
significant increase in intracellular ROS (Figure 34). Conversely, the rise in 
ROS was suppressed by both -TP and -T3 to their basal level (Figure 
34A&B). Therefore, instead of arresting ROS generation, it is more likely that 




    
 
 
Figure 34 Effects of -TP and -T3 in intracellular ROS after APAP- and 
H2O2-induced injury in TAMH hepatocytes. 0 M, 10 M and 50 M of 
each analog were added into TAMH cells concurrently with APAP (A) and 
H2O2 (B) and intracellular ROS levels were performed 24 hr later and 
normalized against each group’s total number of viable cells. n=3 per group; # 
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4.3.5 Effect of -TP and -T3 on lipid peroxidation (LPO)  
Typically, overproduction of ROS mediates oxidative damage 
manifested by LPO, proteins and DNA alterations, which in turn disrupt 
cellular function and integrity. To examine the involvement of -TP and -T3 
in LPO, the levels of MDA formation was quantified colorimetrically by 
following its controlled reaction with TBA. The release of MDA doubled after 
24 hr of APAP and H2O2 incubation compared to the control. In the APAP 
injury model, only 50 M of -T3 managed to suppress the formation of LPO 
significantly (Figure 35A). However, both -TP and -T3 prevented the H2O2 
induced LPO where -T3 appeared to be more effective (Figure 35B). While 
the treatment of 50 M -TP did not prevent the rise in LPO caused by APAP, 
it could suppress LPO caused by H2O2, prompting that it may exert directed 
effect against oxidative stress pathway but not so much in mitigating covalent 
modification of proteins.  
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Figure 35 Effects of -TP and -T3 in LPO formation after APAP- and 
H2O2-induced injury in TAMH hepatocytes. 0 M, 10 M and 50 M of 
each analog were added into TAMH cells concurrently with APAP (A) and 
H2O2 (B) and 24 hr later the intracellular LPO levels were measured using 
TBARS assay. n=3 per group; # p<0.05 versus control; * p<0.05 versus APAP 
























































    
4.3.6 Effect of -TP and -T3 on antioxidant genes activity  
In general, cells have an endogenous antioxidant defense system which 
counteracts the increased oxidative stress in order to maintain the optimal 
cellular functions [197]. The activation of such responses gives proof to the 
role of oxidative stress in the injury and the mechanism of action for any 
observed cytoprotective effects. The expression of HO-1, one of the most 
sensitive oxidant stress-inducible genes is regulated by the redox-sensitive 
transcription factor Nrf-2 [10]. HO-1 and Nrf-2 expressions are frequently 
used as surrogate markers to indicate that the antioxidant machinery is being 
activated at various levels: transcriptional factor as well as effector gene 
responses. To further assess the influence of antioxidant -TP/-T3 against 
the oxidative stress, the protein expressions of HO-1 and Nrf-2 were carried 
out in an immunoblot assay. In the APAP model, both HO-1 and Nrf-2 
proteins were downregulated, and the expressions were not affected by the 
treatment of any protective concentration of -TP/-T3 (Figure 36A). 
However, with H2O2 treatment, Nrf-2 expression was induced while HO-1 
expression was paradoxically reduced. The 50 M of -TP triggered similar 
amount of Nrf-2 expression as in 10 M or 50 M of -T3, which is a 
significant higher level of Nrf-2 compared to the expression in the treatment of 
H2O2 group only (Figure 36B). Even though 50 M of -TP induced Nrf-2 
expression, HO-1 expression remained unchanged compared to the H2O2 
group. On the contrary, HO-1 expression was highly induced following the 
increased in Nrf-2 expression after the treatment of -T3. The results suggest 
that the -T3 is more effective as an antioxidant compared to -TP which is 
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capable of protecting against oxidative stress by inducing the endogenous 
antioxidant defense system.  
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Figure 36 Effects of -TP and -T3 in antioxidant gene activity after 
APAP- and H2O2-induced injury in TAMH hepatocytes. (A) Expression of 
Nrf-2 and HO-1 were determined by immunoblotting after 24 hr concurrent 
treatment of 10 M and 50 M of -TP/-T3 in APAP- or H2O2-injury 
models. Blot shown here was representative from a number of experiments, 
n=3. In densitometry for this representative blot, the relative densities of Nrf-2 
and HO-1 bands were normalized to actin in the same samples for (B) APAP 
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4.3.7 Effect of -TP and -T3 on mitochondrial membrane permeability 
transition (MPT)  
The excessive ROS generated in cells can result in depolarization of 
the mitochondrial membrane followed by the opening of mitochondria 
permeability transition pore. The release of intermembrane proteins leakage, 
such as cytochrome c is a critical early event in the mitochondrially mediated 
apoptosis. Upon release into the cytosol, cytochrome c forms apoptosome with 
Apaf-1 and pro-caspase-9, initiating the caspase cascade apoptosis pathway 
[198]. MPT was evaluated using JC-1 fluorescent probe and a plate reader. 
Red fluorescent indicates healthy cells while green fluorescent indicates 
apoptotic cells. Thus, the mitochondrial depolarization is indicated by a 
decrease in the red/green fluorescence intensity ratio and vice versa. From the 
Figure 37A, treatment of APAP caused a decrease in red/green fluorescence 
intensity but the addition of -TP inhibited the mitochondrial depolarization, 
resulting in a similar level of red/green fluorescence intensity as compared to 
the control. Even though -T3 also reversed the MPT caused by APAP, the 
protective effect against mitochondrial depolarization was not as great as with 
-TP. On the other hand, both -TP and -T3 demonstrated a similar extent 
of inhibition in a dose dependent manner against the H2O2 induced reduction 






    
 
Figure 37 Effects of -TP and -T3 in mitochondrial MPT after APAP- 
and H2O2-induced injury in TAMH hepatocytes. 0 M, 10 M and 50 M 
of each analog were added into TAMH cells concurrently with APAP (A) and 
H2O2 (B) and 24 hr later the MPT levels were detected using JC-1 probe. The 
MPT levels were expressed in the red to green fluorescence ratio. n=3 per 
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4.3.8 Effect of -TP and -T3 on Bcl-xL anti-apoptotic gene  
Bcl-xL, an anti-apoptotic protein was found to be able to associate with 
cytochrome c and block the apoptosome formation and eventually inhibits the 
activation of caspase cascade.  From the Figure 38A, the expression of Bcl-xL 
was at a very low level after the treatment of APAP and H2O2 compared to the 
control. However, the additional treatment of-TP or -T3 did not result in 
higher expression of Bcl-xL in APAP model (Figure 38B). On the other hand, 
50 M of -TP demonstrated significantly higher expression of Bcl-xL in 
contrast to the non-treatment group in H2O2 model. Likewise, both 
concentration of -T3 showed similar extent of Bcl-xL induction, with two 
fold higher than the 50 M -TP in the H2O2 model (Figure 38C). With the 
significant induction effect of Bcl-xL in H2O2 but not in APAP model, -




    
 
 
Figure 38 Effects of -TP and -T3 in Bcl-xL anti-apoptotic gene after 
APAP- and H2O2-induced injury in TAMH hepatocytes. (A) Expression of 
Bcl-xL was determined by immunoblotting after 24 hr concurrent treatment of 
10 M and 50 M of -TP/-T3 in APAP- or H2O2-injury model. Blot shown 
here was representative from a number of experiments, n=3. In densitometry 
for this representative blot, the relative densities of Bcl-xL bands were 
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4.3.9 Effect of -TP and -T3 on caspase 3 activity  
Caspase 3 is the ultimate caspase that carry out the execution phase of 
apoptosis. Importantly, it is a convergent point for both mitochondria 
dependent and mitochondria independent pathways. As mentioned earlier, the 
mitochondria dependent pathway involves the release of cytochrome c and the 
activation of caspase 9 and finally caspase 3 leading to apoptosis. On the other 
hand, mitochondria independent pathway involves the Fas ligand binding 
which induces caspase 8 activation and contributes to the activation of caspase 
3. Thus, caspase 3 is a hallmark of apoptosis that transcends different sources 
of the initiating signals. Caspase 3 was measured using a caspase 3/7 assay kit 
and expressed in the total caspase 3 activity normalized to cell number. 
Caspase 3 activity was highly increased after the treatment of APAP and H2O2, 
with 10 and 2.3-fold higher than the control respectively. Both -TP and -T3 
analogs salvaged the injured cells by halving the total caspase 3 activity in 
APAP model (Figure 39A). Although 10 M of -TP did not significantly 
inhibit caspase 3 activity in the H2O2 model, 50 M of -TP as well as both -
T3 concentration lowered the total caspase 3 activity to half of the activity 




    
  
Figure 39 Effects of -TP and-T3 on caspase 3 activity in APAP- or 
H2O2-induced injury in TAMH hepatocytes. Caspase 3/7 was measured 
after 24 hr treatment of 10 M and 50 M of -TP/-T3 in (A) APAP- or (B) 
H2O2-injury. n=3 per group; # p<0.05 versus control; *p<0.05 versus APAP or 
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4.3.10 Effect of -TP and -T3 on gene regulation in ROS induced 
inflammation  
The inflammatory response is frequently activated as a secondary 
response when cells undergo different types of injury. Hence, by exploring the 
effect of -TP/-T3 against the both pro- and anti-inflammatory protein 
expressions, it is possible to determine the protective stages (before or after 
injury) of -TP/-T3 involved during the cell injury process. As mentioned 
previously (Chapter 3), apart from hepatic regeneration, the inflammatory 
cytokines like TNF-, IL-6 and iNOS were induced upon liver injury. After 
24 hr of APAP and H2O2-induced injury, the mRNA expressions of these 
signals were measured using qRT-PCR. With the treatment of -TP and -T3, 
the expressions of TNF-, IL-6 and iNOS were downregulated compared to 
the of APAP or H2O2 injury group (Figure 40A&B). 50 M of -T3 
demonstrated lowest expressions among the tested analogs and concentrations 
across all the inflammatory responses measured. Contrary to the findings with 
the exosomal study (Chapter 3), these results of marginal inflammatory 
response support that the protective effect of -TP/-T3 was exerted at an 
early stage, before the injury sets in, hence serving as preventive agents 
against APAP and H2O2 injury.  
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Figure 40 Effects of -TP and-T3 on qRT-PCR analysis of iNOS, TNF-
, and IL-6 inflammatory expression. Liver inflammatory responses in 
TAMH cells treated with or without 10 M and 50 M of -TP/-T3 
concurrently in (A) APAP or (B) H2O2, for 24 hr. All the expression were 
normalized against GAPDH expression of the same sample and presented as 
fold-increase over the controls. N=3; # p<0.05 for APAP or H2O2 versus of 
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4.3.11 Effect of -TP and -T3 on protein expressions in liver regeneration  
Although -T3 is known to prevent ROS from exacerbating cellular 
injury, we were keen to explore if there is any additional effect on liver 
regeneration as a complementary healing response. For example, Bajt et al., 
reported that scavenging peroxynitrite with GSH not only reduced oxidant 
stress and tissue necrosis in the liver, it also promoted tissue regeneration 
during APAP-induced liver injury in mice [199]. To examine the regeneration 
effect, a subset of key liver regeneration markers, pMet, NF-kB and PCNA 
were monitored in an immunoblot assay. As detailed in Figure 41A&B, there 
were no significant difference across pMet, NF-kB or PCNA in the APAP 
injury model but the expressions were highly induced in a dose dependent 
manner for -TP and -T3 in H2O2 injury model (Figure 41A&C). The 
expressions of these proteins in -T3 treatment were found to be higher than 
the -TP treatment (Figure 41A). Overall, this result is in similar trend as 








Figure 41 Effects of -TP and-T3 on liver regeneration markers after 
APAP- or H2O2-induced injury in TAMH hepatocytes. (A) Expressions of 
pMet, NF-B and PCNA were determined by immunoblotting after 24 hr 
concurrent treatment of 10 M and 50 M of -TP/-T3 in APAP- or H2O2-
injury models. Blot shown here was representative from a number of 
experiments, n=3. In densitometry for this representative blot, the relative 
densities of pMet, NF-B and PCNA bands were normalized to actin in the 
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4.3.12 Summary 
 
Table 4 Summary on the effects of -TP and-T3 against APAP and 
H2O2-induced injury in TAMH hepatocytes. 
Toxicant APAP H2O2 
Treatment - -TP (M) -T3 (M) - -TP (M) -T3 (M) 




#  * * * # * * * * 
Pre-
treatment 
# = * = * # * * * * 
GSH  # = = = = # * * * * 
ROS  # * * * * # * * * * 
LPO  # - = - * # - * - * 
Antioxidative 
genes 
Nrf-2  = = = =  =    
HO-1  = = = =  = =   
MPT  # * * * * # * * * * 
Anti-
apoptotic gene 
Bcl-xL  = = = =  =    
Anti-
apoptosis  
Caspase 3 # * * * * # = * * * 
Inflammatory 
genes 
TNF- # * = * * # * = = = 
IL-6 # * * * * # * * * * 
iNOS  = = * * # = = * * 
Liver 
regeneration 
pMet  = = = =      
NF-B  = = = =  =    
PCNA  = = = =      
 and  higher or lower than control or  APAP or H2O2 alone; = no difference with 
APAP or H2O2 alone; # p<0.05 compared to control; symbol in red with * p<0.05 
compared to APAP or H2O2 alone 
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In summary, -T3 stood out as the most promising hepatoprotective 
agent among the tocotrienol analogs. Together with -TP, they were found to 
be effective in the prevention against APAP and H2O2 injuries. The effect 
against oxidative stress (H2O2 injury model) is more profound and -T3 
demonstrated more outstanding protective effect compared to -TP (Table 4). 
They preserved the cell viability by acting against the build-up of ROS and its 
downstream pathway which inhibited the injury and initiation of apoptosis. In 
addition, hepatocytes regeneration was activated along with the protection 
shown in H2O2 model, emanating a multi-pronged effort towards 
cytoprotection. The significance of this effect will be discussed. 
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Figure 42 Proposed protective mechanism of Vitamin E analog in DILI. 
 
In this chapter, we hypothesize that -T3 is a principal Vitamin E 
isomer that can play an effective role in protecting and attenuating the 
xenobiotic-induced liver injury due to its antioxidant properties (Figure 42). 
To prove this hypothesis, we explored such effect by applying previously 
developed and well-defined mechanism of toxicity - APAP and H2O2 in vitro 
using TAMH cells. Cytotoxicity of different T3 analogs were first explored in 
the cell viability followed by the cellular uptake assay and the effect were 
compared with -TP. Accordingly, our experiments have demonstrated that 
the -T3 is the analog that consistently preserved the highest cell viability 
after the injury of APAP and H2O2 while -T3 and -T3 did not exert any 
protective effect. Notably, -T3 appeared to exert both a preventive and 
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protective agent. It acted as an antioxidant by reacting with ROS, protecting 
the cells from injury while inducing the remnant hepatocytes to regenerate. 
The powerful antioxidant properties of -T3 were elicited by its effectiveness 
against the H2O2-injury model compared to the APAP model. We qualified the 
antioxidant potential of these -T3 by firstly investigating the relative 
hepatoprotection capacities of each analog and the underlying mechanisms by 
which analog exerted its cytoprotective action. 
Within the same family, different isoforms of T3 (which differ in their 
number of methyl groups), also exhibited variable biological activities. While 
various studies have indicated -T3 is the most potent antioxidant among T3 
analogs, -T3 [200] and -T3 [201, 202] have also been claimed to have better 
antioxidant properties than -T3 respectively. For this reason, the effects of all 
three T3 analogs were explored in our DILI study. However, other than -T3, 
none of the concentration of -T3 and -T3 demonstrated protective effect 
against APAP- or H2O2-injury. These findings somewhat agree to the growing 
consensus that -T3 and -T3 are more pronounced in anti-proliferation/pro-
apoptotic properties among all the natural existing T3. The identified relative 
suppression of proliferation potencies were as follow: -T3 > -T3> -T3 [203, 
204]. Both -T3 and -T3 were shown to inhibit growth of breast cancer cells 
irrespective of estrogen receptor status [112, 114]. The anti-cancer properties 
of -T3 was proven in human hepatocellular carcinoma HepG2 cells, where -
T3 exerts more significant anti-proliferative effect than any other T3 analogs, 
was found to induce apoptosis and tend to induce S phase arrest [113]. Apart 
from that, -T3 was also found to inhibit proliferation of human hepatoma 
Hep3B cells, through activating the caspase cascades while upregulating pro-
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apoptotic genes, Bax and truncation of Bid [205]. Due to this reason, only -
T3 was considered therapeutic in our context and further explored in the 
protective mechanistic study in vitro. 
The protective effects of Vitamin E against acute and chronic injuries 
induced by CCl4 or D-galactosamine have been reported in several studies 
[206-209]. However, these toxicants are not truly representative of drug-
induced toxicities, and any subtle differences in the resulting responses cannot 
be presumed. Moreover, recent literatures have also expounded on the 
diversity of Vitamin E isomers and the variety of biological effects each can 
mediate. As claimed by Packer et al., the effectiveness of different Vitamin E 
isomers may involve two main factors, i.e., the substituent on the chromanol 
nucleus “head” (among -, -, - and - analogs) and the properties of the side 
chain “tail” (among TP and T3 family) [210]. Yoshida et al., reported that the 
reactivities of T3 against peroxyl radical in homogenous solution were 
substantially the same with the corresponding TP and the relative reactivities 
decreased in the order of  [211]. These antioxidant capacities in 
organic solution seemed to depend on the methyl substituent on the chromanol 
ring instead of the side chain. In contrast to the homogenous solutions, the 
mobility of the molecule in membranes becomes important and may depend 
on the structure of the hydrophobic side chain.  
In contrast to the similar radical scavenging activity between -TP and 
-T3 found in hexane, the -T3 has been reported to possess higher 
antioxidant efficacy against oxidative damage compared to -TP in liposomes 
and rat liver microsomes [122]. Based on the differences in the tail structure, it 
has been suggested that the unsaturated side chain of -T3 contributes to the 
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stronger disordering effect on membranes and therefore, compared to -TP, -
T3 distributed more uniformly within the membrane [122]. Studies also 
indicated that -T3 located nearer to the membrane surface which may 
contributes to greater recycling activity correlating with the inhibition of LPO 
[212]. These properties likely enhanced the interaction of chromanols with 
lipid radicals. However, these studies were performed in ex vivo model and 
thus the antioxidant efficacy might differ in contrast with in vitro or in vivo 
studies. Similarly, the Vitamin E analogs cellular uptake assay performed here 
may include some adsorption of the TP or T3 analogs to the outer surface of 
the plasma membrane even after several wash with PBS. However, it was 
believed that these adsorbed analogs may also contribute to the cytoprotective 
and antioxidative effect. 
To date, the effect of -T3, an isomer of therapeutic significance, 
against DILI has not been explored in any cell or animal model. -T3 has been 
reported to exert potent neuroprotection effect, although some claimed that the 
-T3 is the most potent analog among others [116] while another reported 
similar cytoprotection effect of -T3 with -TP [195]. Nevertheless, both 
studies demonstrated neuroprotection of -T3 at nanomolar concentration. 
Contrary to that, the hepatoprotective effects of -TP/-T3 observed in this 
study occurs at micromolar concentration. Likewise, similar to the 
neuroprotection study, -T3 demonstrated more profound cytoprotection 
against APAP or H2O2 injury than -TP.  
Barring any different in free radical scavenging potential, the superior 
protection shown by -T3 here could be attributable primarily to the higher 
cellular uptake rate or higher cellular content of -T3 in the cells. Saito et al., 
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reported that the cellular content of -T3 accelerated during the first 6 hr of 
incubation and plateau after that whereas -TP increased linearly from 
incubation time up to 72 hr in Jurkat cells [213]. The higher cellular uptake is 
also due to the higher rate of incorporation into cells, as reported by several 
other studies [214, 215]. Similarly, Yasukazu et al., reported that -T3 more 
readily transferred between membranes and incorporated into membranes than 
-TP using ESR assay [211]. In a concurrent treatment study, it has been 
claimed that the smaller protective effect of -TP compared to the -T3 is due 
to the slower rate of incorporation whereas the 24 hr pre-treatment 
demonstrated comparable protection between two analogs at the same 
concentration [195]. This study further confirmed the greater potency of -T3 
mainly owing to its higher rate of incorporation which may be due to the 
larger inter-membrane mobility of -T3 than -TP.  
With 24 hr incubation in TAMH cells, the cellular content of -T3 was 
1.9 and 2.5-fold higher than -TP at the concentration of 10 M and 50 M. 
This result is in accordance with the findings where -T3 has been reported to 
have cellular uptake of 6.5-fold higher than -TP in Jurkat cells [213] and 
16.4-fold in primary cortical neurons [195]. It may be noteworthy that by 
comparing at similar intracellular concentration attained, the cytoprotection 
and resistance against oxidative stress effect of -T3 and -TP was found to 
be identical [195, 215, 216]. In summary, these observations suggest that the 
different cytoprotective effects of -T3 and -TP observed in this study could 
be arise from differential intracellular accumulation other than the difference 
in antioxidant potency of each analog. Nonetheless, the higher cellular uptake 
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of -T3 only holds in the in vitro system while in vivo experiments 
demonstrated higher bioavailability and tissue distribution of -TP [196] due 
to its highest affinity for α-tocopherol transfer protein (TTP) [217] and also 
faster metabolism of α-T3 compared to α-TP in the liver [218]. Therefore, the 
biological action of α-T3 observed in the cell culture model may have 
different outcome in the in vivo system. 
Even though there is a big discrepancy on the cellular uptake between 
in vitro and in vivo, the cell culture model is often used to elucidate the 
underlying cytoprotective mechanisms of -T3/-TP. Different oxidative 
stressors can be used in vitro to evaluate and compare the direct antioxidant 
effects, whereas many factors such as bioavailability, effect of dosage and 
duration etc., should be taken into consideration in its assessment for the in 
vivo model. As a consequence, we examined the cytoprotective mechanism of 
-T3 and -TP against APAP and H2O2 toxicants in vitro in this study.  
In a normal cell, the redox system is well maintained by robust 
endogenous antioxidant systems. These antioxidants include antioxidant 
enzymes (e.g., SOD, Gpx, CAT etc.), nutrient-derived antioxidants (e.g., 
ascorbic acid, TP and T3, carotenoids, GSH etc.) and other metal binding 
proteins (e.g., ferritin, lactoferrin, albumin etc.) [219]. This study clearly 
demonstrated that the APAP and H2O2 toxicants caused a multitude of 
antioxidant perturbations including the depletion of GSH, induction in ROS 
generation and LPO, opening of MPT pore and activation of caspases in the 
hepatocytes. The treatment of -TP and -T3 were able to reverse these 
adverse effects when the redox balance was challenged. Therefore, we 
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considered the effects of -TP/-T3 at each stage in ROS defence system as 
discussed under section 1.4.1 (Figure 4). 
The first line defence mechanism involves the suppression of free 
radicals formation with both GSH and Vitamin E. GSH involves in the 
catalytic removal of reactive species while GSH and Vitamin E both engage in 
the reduction of active oxygen species [219]. It has been claimed that the 
regeneration of Vitamin E from its oxidized state is a GSH-dependent process 
[220] while some clinical studies claimed that the pharmacological doses of 
Vitamin E enhance red blood cell levels of reduced glutathione [221] and 
plasma GSH/GSSG ratio in humans [222, 223]. Khanna et al., reported that 
the -T3 at its antioxidant concentration in micromolar were able to restore 
the level of GSSG/GSH [224]. Parallel with these findings, the result in this 
study showed that the GSH level in H2O2 treated cells remained significantly 
higher after the treatment of both -TP and -T3 compared to the control. On 
the contrary, the treatment of -TP/-T3 did not affect the GSH level in 
APAP injury model. A plausible explanation for this effect could be that the 
GSH used to reduce the H2O2 into GSSG could have been restored by -TP/-
T3 thus maintaining its high GSH level, whereas GSH committed to 
conjugation with NAPQI in APAP model may not be readily restored by the 
same treatment. 
In spite of ROS being removed by the first line defense antioxidants, 
free radicals still formed in vitro and initiate oxidative stress. As a second line 
defense system, antioxidants scavenge and quench the free radicals before 
they attack on the biological molecules. Apart from H2O2, APAP has also been 
suggested to be closely related to cause LPO. It was found that both the 
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lipophilic compounds, -TP and -T3 resided in the intracellular lipid bilayers 
and thus were able to block the electron transfer involved in the initiation and 
propagation of LPO [225]. As reported, Vitamin E demonstrates significant 
inhibition of LPO after APAP and CCl4 injury in mouse models [226, 227]. 
Physiologically, its structural characteristics enable it to act as a cell 
membrane stabilizer. It has been reported that -T3 was more potent in 
scavenging the very reactive OH and lipid peroxyl radical (ROO) in 
liposomes than -TP [212]. It was also found that -T3 exerted more 
pronounced inhibitory effects on LPO in rat liver and murine microsomes than 
-TP [122, 228]. Consistent with these findings, in the present study it was 
found that both analogs have the ability to block the increase in LPO in the 
H2O2 injury model, but the inhibition of LPO at 50 M -T3 is greater than 50 
M-TP. Moreover, the same concentration of -T3 demonstrated lower 
LPO level in H2O2 compared to APAP injury. 
Besides playing a vital functional role in maintaining the redox balance 
in the cells, mitochondria is also a major source of ROS production. The 
binding of ROS to the intramitochondrial membrane which result in LPO can 
subsequently cause the release of endogenous ROS into the cytoplasm during 
the MPT pore opening. Thus the mitochondria transmembrane potential 
transition marks a critical point in the execution of apoptosis. Based on the 
study of Khanna et al., both homocysteic acid and linoleic acid resulted in 
marked increase in [Ca
2+
]i and simultaneous loss of mitochondrial membrane 
potential but were prevented by the presence of -T3 [224]. The same trend 
was observed in this study where the MPT decreased with the increased in 
LPO caused by both APAP and H2O2 toxicants. However, the perturbations in 
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MPT were successfully inhibited with the treatment of -TP and -T3 and the 
levels of MPT were successfully restored back to the normal control level after 
the treatment of 50 M of each analog.  
The ROS induced mitochondria dysfunction is a continuous process 
and accumulation can exacerbate oxidative damages leading to detrimental 
cell death. -TP has been reported to inhibit ROS increased in a selenium-
deficient model [213] while -T3 was reported to prevent the raise in ROS 
caused by homocysteic acid and linoleic acid in HT4 neural cells [224]. In a 
glutamate-induced neurotoxicity cell study, even though -TP/-T3 did not 
inhibit the decrease in GSH level, ROS level was significantly suppressed at 
the respective neuroprotection concentrations [195]. Similarly, -T3 was 
reported to have no effect in sparing the glutamate-induced depletion of 
intracellular GSH but it completely prevented the accumulation of intracellular 
peroxides even if the -T3 was treated 5 hr after the glutamate treatment [214]. 
Collectively, the findings of these studies where prevention of ROS release 
and mitochondrial stress were manifested despite an initial GSH depletion 
indicate that -TP and -T3 are acting on different levels of protection. Apart 
from the preventing measure, -TP and -T3 were also able to exert their 
function during injury and post-injury. Our results appeared to confirm with 
these studies where -TP/-T3 minimized the intracellular ROS after the 
injury of APAP and H2O2 to a level which is similar to the control.  
Upon the MPT pore opening, cytochrome c is released into the 
cytoplasm. The release of cytochrome c, a critical component of caspase-3 
activation, can be blocked by Bcl-xL anti-apoptotic protein. This phenomenon 
is captured in Figure 38C where the Bcl-xL expression increased after -TP/-
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T3 treatment followed by decrease in the caspase 3 activities in H2O2 model 
(Figure 39B). However, this was not manifesteddoes not hold in APAP injury 
model. From the findings in this study, the increased in caspase activity 
induced by APAP was found to be 10 fold higher compared to control while 
the increment in H2O2 was only about 2 fold higher. This difference could be 
due to the different injury pathway induced by each toxicant. Aside from 
inducing oxidative stress pathway, APAP also induces the mitochondria 
independent pathway, potentially through the induction of TNF- (as shown 
in Figure 3). This could explain the findings where -TP/-T3 having 
minimal effect in Bcl-xL induction still demonstrates significant suppression of 
caspase 3 activity in APAP model. It is worth noting that from our findings, 
both -TP and -T3 were involved in the inhibition of mitochondria 
dependent and independent apoptosis process.  
Inflammation is often associated with overproduction of ROS that play 
an important role in toxicant-induced acute liver injury. Following the 
exposure to hepatotoxic chemicals, the generated oxidative stress can trigger 
inflammatory cytokine responses in injured hepatocytes and Kupffer cells 
[229]. These cytokine responses involve in a number of pathological, 
protective and repair events [230]. The main purpose of these cytokines 
activation is to orchestrate the removal of dead or dying cells, where it is 
essential for regeneration of lost tissue. In the study of using APAP or CCl4 as 
toxicants, the TNF- and IL-6 were found to be highly induced [231, 232]. 
Similarly, we observed a marked rise in the release of IL-6 and TNF- upon 
the APAP induced injury. As reported, the TNF- and iNOS inflammatory 
responses were inhibited when berberine was found to be effective in 
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protecting the liver from acute CCl4 injury through scavenging free radical and 
attenuating oxidative stress [229]. Similarly to this study, the TNF-, IL-6 and 
iNOS genes were downregulated after the treatment of -TP/-T3. These anti-
inflammation results indicate that the -TP/-T3 act as preventive agents in 
inhibiting the oxidative stress and apoptosis, resulting in reduce toxicant-
induced liver injury which with less toxicity there was less induction in 
inflammatory responses. Taken together with the previous findings, this anti-
inflammation outcome complements the protective effect of -TP/-T3 
against the APAP and H2O2-induced injury at the ROS preventive or early 
injury stage.  
Finally, the induction of oxidative stress can also lead to impairment in 
liver regeneration. Recently, Nrf-2 has been shown to play an indispensable 
role in liver regeneration where Nrf-2-deficient mice demonstrated significant 
delay in regeneration after PH [233]. Nrf-2 is known to regulate the cellular 
antioxidant defence system, thus the deficiency in Nrf-2 transcription factor 
will result in enhanced oxidative stress due to reduced expression of ROS-
detoxifying enzymes. Apart from that, deficiency in Nrf-2 which demonstrated 
the increased susceptibility of the mice to APAP also suggests the important 
role of Nrf-2 in the regulation of GSH synthesis and cellular detoxification 
processes [234, 235]. It has been known that the Nrf-2 pathway which is 
directly induced by APAP can be activated either through modification of 
Keap1 or solely via the substantial depletion of GSH due to NAPQI [236]. 
HO-1 is a Nrf-2-targeted gene and the induction of HO-1 in acute and chronic 
hepatic inflammation rodent models resulted in improvement of liver damage 
and downregulation of proinflammatory cytokines [237]. From the results 
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shown in this study, -T3 possesses a stronger effect than -TP and was more 
effective in inducing the suppressed endogenous antioxidative defence 
mechanisms of Nrf-2 and HO-1 against the H2O2 oxidative stress injury. Due 
to this, a significant trend of elevation in the regeneration markers of pMet, 
NF-kB and PCNA were observed. Nonetheless, the negative effect of -TP/-
T3 in the Nrf-2 and HO-1 expression in APAP injury resulted in no difference 
in the regeneration markers. These findings were in agreement with the 
previous studies shown where Nrf-2 is crucial in inducing liver regenerating 




    
4.5 CONCLUSION 
 
In conclusion, -TP/-T3 demonstrated protective effects against 
APAP and H2O2-induced liver injury by arresting free radicals, blocking 
mitochondria stress, inhibiting oxidative stress, inducing endogenous 
antioxidative stress and thus reducing injury-triggered inflammatory responses 
while inducing hepatocyte regeneration upon injury (Figure 43). Overall, these 
protective events happening at different time sequence may not be mutually 
exclusive but complementary. Finally, -T3 seems to be a more potent 
hepatoprotective analog than -TP probably due to its higher intracellular 
content. Taken as a whole, both -TP and -T3 analogs demonstrated more 
profound protective effect against the oxidative stress in H2O2 compared to 
APAP model.  
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Figure 43 Proposed -T3 protection pathways in APAP- and H2O2-
induced liver injury in TAMH cells. -T3 was able to inhibit various stages 
of injury which leads to cell death while inducing the endogeneous anti-
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Results on combination therapy of  
exosomes and -T3 
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5.1 INTRODUCTION 
 
Looking back at our overall objective as detailed in chapter 1, the 
proposed strategies in managing DILI include limiting injury at prophylaxis 
stage and stimulating the remnant liver to regenerate when injury sets in. Our 
intended strategy was aimed to address each of these paradigm with novel 
agents, and then to characterize the mechanism of their action. From our 
subsequent findings, -T3 was shown to exert its antioxidant properties in 
quenching and scavenging the ROS at the prevention stage while exosomes 
demonstrated regenerative effect in the remnant hepatocytes after the APAP 
and H2O2 injury. These promising protective effects of both exosomes and -
T3 act rather specifically on different stages of injury, with little evidence for 
cross activity. For this reason, it would be synergistic or additive if both agents 





    
5.2 EFFECT OF EXOSOMES AND -T3 AGAINST APAP- AND H2O2-INDUCED 
LIVER INJURY IN CELL VIABILITY 
 
As a preliminary study on the combination therapy, the optimized 
concentration of exosomes and -T3 were introduced together and 
administered concurrently with either APAP or H2O2 toxicants for 24 hr in 
TAMH cells. Compared to each treatment of either exosomes or -T3, the 
combination therapy of exosomes and -T3 demonstrated higher cell viability 
in both injury models (Figure 44). As expected, the cell viability of the 
combination therapy in H2O2 (83%) increased slightly higher than APAP 
injury (72%), probably due to the anti-oxidant potency of -T3. Although the 
effect of exosomes in retaining higher cell viability is not as great as -T3, 
combination therapy demonstrated even better improvement in total number of 
viable cells and this supports the importance of preserving the remnant liver 
and inducing its regeneration to overcome DILI. Based on this result, it is 
reasonable to speculate that the protective mechanisms of exosomes and -T3 











Figure 44 Combination therapy of exosomes and -T3 in APAP- and 
H2O2-induced liver injury in TAMH cells. 0.1 g/ml of exosomes or 50 M 
of -T3 or the combination of both agents were added to respective 
concentration of APAP (A) and H2O2 (B) concurrently and MTT were 
performed 24 hr later. Cell viability was normalized against vehicle control 
group and expressed in percentage. n=6 per group; * p<0.05 versus APAP or 
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5.3 DISCUSSION ON THE COMBINATION THERAPY OF EXOSOMES AND -T3  
 
The benefit of combination therapy has been proven in many cases, 
including a clinical study using prednisone and ursodesoxycholic acid (UDCA) 
on non-APAP-induced drug induced severe liver injury patients [238]. 
Previously, steroids were useful in limiting tissue damage caused by 
inflammatory responses of the immune system within the liver [239, 240] 
while UDCA protects hepatocytes and cholangiocytes against the cytotoxic 
and pro-apoptotic effects of bile acids and stimulates hepatobiliary secretion 
[241]. The treatment for patients with both drugs as combination therapy has 
led to a more rapid reduction in bilirubin and transaminases after DILI. 
Therefore, treatment with combination therapy using agents targeting the 
different mechanisms of action would be beneficial and more effective than a 
mono-therapy. Similarly, the therapeutic agents used in this study also target 
different injury pathways; -T3 prevents the ROS generation induced injury at 
the prophylaxis stage while exosomes induce remnant hepatocytes 
regeneration to preserve the hepatocytes function at the post-injury stage. In 
light of this, the promising results of this combination therapy deserve further 
exploration in order to elucidate the mechanisms of action and to study the 
feasibility of this combination therapy in vitro and in vivo. It would be 
interesting to find out the reciprocal interactions between exosomes and -T3 
in the xenobiotics-induced injury pathway and how do they complement each 
other in protecting the hepatocytes from injuries at the molecular level.  
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Conclusion & future perspectives  
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6.1 RECAPITULATION OF OVERALL HYPOTHESIS AND STUDY AIMS 
 
The major aim of this research project was to explore the potential 
regenerative/protective effect of MSC-derived exosomes and -T3 as novel 
agents in overcoming DILI and other acute liver injuries. By investigating the 
mechanistic basis for their protective effect if any, we could determine if they 
exert protection at different stages of the liver injury, and hence amenable for 
combinatorial use. The first hypothesis made was the size purified subset of 
exosomes derived from MSC-CM can play a role in mitigating xenobiotic-
induced liver injury. With that, we investigated the cytoprotective effect of 
exosomes in vivo DILI model, followed by in vitro effect on different 
hepatotoxicants with distinct mechanism of toxicities and finally explored the 
exosomes potential hepatoprotection or hepatoregeneration pathways. The 
second hypothesis made in this study was that -T3 has the antioxidant 
potential to protect from xenobiotic-induced liver injury. In view of that, the 
specific aim was to investigate the cytoprotection effect of -T3 as an 
antioxidant in vitro against different mechanisms of toxicities induced by 
different hepatotoxicants and finally explore their potential hepatoprotection 
or hepatoregeneration pathways. Lastly, based on the hypothesis of both 
protective agents, preliminary study on the combination of exosomes and -
T3 was explored in vitro to determine the feasibility of these agents as a 




    
6.2 CONCLUSION OF MSC-DERIVED EXOSOMES  
 
In the first part of this study, in vivo study was performed using CCl4-
induced acute liver injury model. It was observed that in exosomes treated 
mice, transaminitis observed with the raised levels of AST and ALT were 
significantly lower compared to the non-exosomes treatment group. 
Histologically,  liver tissues for CCl4 group showed moderate necrotic 
hepatocytes while in the exosomes treatment group, only minimal necrotic 
cells were found. The regenerative effect of exosomes was further investigated 
in the in vivo study. The immunoblot assay showed that the exosomes 
treatment group significantly upregulated the hepatic protein expressions of 
NF-B, cyclin D1 and cyclin E relative to the untreated. The activation of 
proliferation was further confirmed in the PCNA IHC staining on the liver 
tissue. These findings were supportive of the postulation that the exosomes 
may protect the liver injury while inducing liver regeneration in the remnant 
hepatocytes. Overall, these findings corroborate well with the other studies on 
MSC-CM protection against liver injuries. [132-136]. 
To broaden the potential application of exosomes, the therapeutic 
effect of exosomes against different hepatotoxicants with defined mechanisms 
of toxicity was examined in vitro. It was found that at 0.1 g/ml, exosomes 
showed consistent cytoprotection against APAP- and H2O2-induced liver 
injury across the three different cell lines. These same effects demonstrate the 
potency of exosomes across a range cell lines used. These cytoprotection 
results could be attributed to either the protective or regenerative effect of 
exosomes, both of which could result in higher cell viability after the injury.  
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In view of the cytoprotection of exosomes, the underlying mechanisms 
of each injury pathway were investigated. It was found that the exosomes 
induced higher TNF-, IL-6, iNOS, COX-2 and MIP-2 gene expression after 
both injuries. These genes which have been proven previously in other studies 
were prominent in initiating liver regeneration. These results suggest that the 
effect of exosomes might be attributed to the regeneration effect which leads 
to higher cell proliferation and viability. To further strengthen the regenerative 
effect of exosomes, different cell cycle markers were examined. Based on 
Western blot assay to quantify protein expression changes, NF-B and pStat-3 
transcription factors in cells following exosomes treatment were highly 
expressed during G1 phase in cell cycle compared to the non-exosomes 
treatment group in both injury models. Subsequently, the search for 
biochemical evidence of active cell cycling was pursued by monitoring cyclin 
D1 and PCNA expressions. The exosomes treatment demonstrated increased 
in protein expression of cyclin D1 and PCNA during APAP- and H2O2-
injuries. These findings confirm that MSC-exosomes promote hepatocyte 
regeneration and proliferation during acute liver injury in vitro. 
Besides promoting regeneration, the effect of exosomes in protecting 
the hepatocytes from the xenobiotics-induced apoptosis was investigated. The 
results showed that the exosomes treatment significantly suppressed the 
activity of caspase 3 in APAP- but not in H2O2-injury model. This contrasting 
outcome highlights the reality that the cytoprotective effect of exosomes may 
not address every form of drug-induced toxicity. A possible explanation for 
the lack of effect against caspase 3 in H2O2-injury model could be because the 
exosomes has better inhibitory effect against the protein binding and 
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dysfunction instead of circumventing oxidative stress at the upstream of 
caspase 3 pathway. Despite this, further increase in anti-apoptotic protein, Bcl-
xL expression after the treatment of exosomes was demonstrated in both injury 
models. However, no significant difference was observed between the 
exosomes treated or non-treated group in the antioxidative genes. One possible 
inference is that the exosomes may not regulate the anti-apoptotic effect 
through antioxidative genes. In accordance with the in vivo results, these in 
vitro results appear to confirm that the exosomes treatment could protect the 
liver and reduce the injury level through regulating the anti-apoptosis, 
proliferative and regenerative hepatic responses to liver damage. 
Nonetheless, this is the first study to show the protection and 
regeneration effect of MSC-derived exosomes against xenobiotics-induced 
liver injury. This study of exosomes may provide an important contribution as 
an alternative therapeutic solution in treating acute liver injury. The exosomes 
hold several benefits against the MSC therapy because no immune response 
will be elicited, nor any inherent or xenobiotic-mediated toxicity and, thus it is 
safer to use as they are nonviable. Besides that, hESC line being the source of 
the exosomes contributes to a reproducible, scalable and relatively inexpensive 
approach to solving the problem of inconsistency in quality and limited supply. 
This promising discovery of MSC-derived exosomes has taken a major step 
towards a non-cell-based adjunctive therapy for the treatment of liver injury.  
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6.3 CONCLUSION ON T3   
 
Even though exosomes were shown to be promising in inducing the 
remnant hepatocyte regeneration in overcoming DILI, a notable absence of a 
mechanism to arrest the source of injury draws our attention to additional 
strategies. To address this research gap, our second aim of this project is to 
explore the potential protective effect of T3, especially -T3 compared to -
TP in overcoming DILI in vitro. In characterizing the -TP and T3 analogs, 
cytotoxicity and cellular uptake of each analog in TAMH cells were examined. 
It was found that -TP and -T3 did not exert toxicity up to 100 M of 
concentration while 10 M of -T3 and -T3 were toxic to the cells and 
caused a significant drop in cell viability. The dose dependent study of cellular 
uptake revealed accelerated incorporation of analogs, with the highest uptake 
of -T3, followed by -T3, -T3 and lastly -TP remained unchanged 
throughout the concentration tested. The results correlate well with the other in 
vitro studies on the lower cellular uptake of -TP than -T3 [213-215]. 
Subsequently, the potential therapeutic effect of -TP and T3 analogs 
against APAP and H2O2 was examined in vitro. Based on the cell viability 
assay, -TP and -T3 demonstrated dose dependent suppression of APAP- 
and H2O2-induced toxicity while -T3 and -T3 failed to retained higher viable 
cells after both injuries, in concurrent and pre-treatment models. These 
cytoprotective effects demonstrated by -TP and -T3 may be attributed to 
their antioxidant properties resulting in protection or regeneration against the 
toxicants induced liver injury. Overall, -T3 demonstrated higher cell 
recovery over -TP at the same treatment concentration. This finding suggests 
 168 
    
that there is a probable relationship between the cellular uptake and the 
protective effect of -TP and -T3 towards APAP and H2O2-induced liver 
injury. 
After confirming the cytoprotection of -TP and -T3, the 
mechanisms of antioxidant reactions against each injury pathway were 
investigated. It was found that both -TP and -T3 were effective in restoring 
the depleted GSH level in H2O2 but not in APAP injury model. The lack of 
response with APAP is likely due to the irreversible nature of the GSH 
conjugation with reactive metabolite such as NAPQI. Under such 
circumstances, dysfunctional proteins can only be salvaged by de novo 
synthesis. On the other hand, cytoprotective concentration of -TP and -T3 
inhibited the increased in intracellular ROS, LPO and MPT pore opening after 
the injury of both toxicants. However, only -T3, but not -TP was shown to 
induce antioxidant proteins, Nrf-2 and HO-1 in H2O2 injury. It seems that the 
antioxidant effect of -T3 is more potent than -TP and this could be due to 
its better uptake by the cells. The overall results appear to confirm the 
antioxidant effect of both -TP and -T3 in counteracting with the oxidative 
stress induced injuries. 
Apart from antioxidant properties, the anti-apoptotic effect of -TP 
and -T3 was investigated in APAP- and H2O2-induced liver injury. The 
results demonstrated that the -TP and -T3 significantly suppressed the 
activity of caspase 3 in both injury models while inducing anti-apoptotic 
protein, Bcl-xL expression in H2O2 injury. These results indicate that -TP and 
-T3 may also regulate the anti-apoptotic effect through antioxidative genes. 
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Finally, effect of -TP and -T3 against the inflammatory and 
regenerative response in both toxicants induced injuries were examined. It was 
shown that the inflammatory responses were downregulated while the liver 
regeneration markers expressions were highly induced with the treatment of 
-TP or -T3. Taken together, these results appear to confirm the 
antioxidative properties of -TP and -T3 in protecting the hepatocytes from 
injury at the prophylactic stage and inducing the remnant hepatocytes to 
undergo regeneration, while -T3 demonstrated higher potency than -TP 
possibly owing to its higher content in the cells. 
Overall, this study has provided conclusive evidence that the -T3 
possesses high potency of antioxidant properties which can prevent the 
oxidative stress injuries at different stages. The mechanistic study also 
provides valuable insights that antioxidants such as -T3, could somehow 
limit the injuries caused by oxidative stress due to the reactive metabolite 
formed from drugs. This finding is useful and offers an alternative treatment 
for patients where the medicine could be consumed together with -T3 as 




    
6.4 CONCLUSION OF EXOSOMES AND -T3 COMBINATION THERAPY 
 
Given that exosomes and T3 operate on different protective 
mechanisms, we further envisaged the effect of the combination therapy of 
exosomes and -T3 in vitro against DILI in a preliminary study. Based on the 
cell viability assay, the combination therapy demonstrated highest total 
number of viable cells compared to each single treatment after the APAP- and 
H2O2-induced injury. This indicates that both agents can act in concert 
complementing the protection against DILI. The different mechanisms of 
actions of exosomes and -T3 which act against different targeted pathways in 
DILI provide a therapeutic advantage where both the prevention at pre-injury 
and injury stage and recovery on the post-injury stage have been addressed.  
  
 171 
    
6.5 OVERALL CONCLUSION 
 
Collectively, these research studies have demonstrated regenerative 
evidence of MSC-derived exosomes on remnant hepatocytes after xenobiotics-
induced injury and antioxidative properties of -T3 in protecting hepatocytes 
injuries caused by oxidative stress during DILI. The combination therapy of 
these therapeutic agents provides significant advancement to the field of 
hepatoprotection and hepatoregeneration as they offer a comprehensive 
protection against DILI through limiting injury at prophylaxis stage while 
stimulating remnant liver regeneration post-injury. What remains 
insurmountable is that the current available treatment agents only managed to 
prevent DILI at the prophylaxis or at the early stage of injury, any delay in the 
treatment fails to protect the liver from injury. Nonetheless, the combination 
of exosomes and -T3 holds several advantages over the current available 
treatment for DILI: (1) both agents are natural substances found in the body 
and thus within a safe range of dosage, these agents are able to minimize the 
possibility of xenobiotics (e.g., with the use of exogenous small molecules like 
NAC) induced idiosyncratic liver injury; (2) this combination therapy may be 
able to broaden the protective effect over a longer time course of injury, 
control the extent of injury and thus may minimize the events of liver failure; 
(3) It is also envisioned that exosomes therapy may over take the liver 
transplantation treatment in the near future owing to its non-viable and 
regenerative properties. Even though these studies were performed on the 
stages of pre- treatment and concurrent treatment instead of post-injury 
treatment, the results of these therapeutic agents can also be applied and 
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translated into clinical use. For instance, patients who have pre-existing or 
history in liver disease which increase their susceptibility to drug toxicities 
may take these therapeutic agents concurrently with the medications 
prescribed as a prophylactic step to prevent toxicities. In conclusion, we have 
successfully addressed the research problems encapsulated by these two novel 
agents, and paved the way for future optimization to advance the clinical 





    
6.6 RECOMMENDATIONS FOR FUTURE WORK 
 
There are several interesting directions for future work in the areas of 
research presented in this thesis. 
 This study did not explore the uptake of exosomes in vivo. This is an 
important consideration to gain insights into the disposition of the 
exosomes to optimize delivery. We have not evaluated this aspect 
because the injected effective dosage (0.4 μg per mouse) was fairly 
low. Thus this is beyond our detection because once the exosomes 
enters the hepatocytes, it may fuse with the cell membrane and release 
its contents. Furthermore they may be metabolized in the liver in a 
short time frame and excreted from the body. Future research is 
therefore needed to develop a more sensitive labelling technique or 
detection method which may help to improve our understanding of the 
dynamics of exosomes and its biodistribution in the organs after 
administration in vivo. Verification of protein supplementation by 
demonstrating the physical transfer of functional glycolytic enzymes 
from MSC exosomes to reperfused myocardium is currently limited by 
a lack of suitable technology to track and monitor the metabolic fate of 
an exosome and its contents. The main issue is that the efficacious 
dosage is relatively low at 0.1–0.4 μg per mouse. More sensitive 
labeling techniques are needed to explore the dynamics of exosomes 
after in vivo administration. 
 Being an exploratory study, this work only involves proving the 
concept of exosomes effect as a whole system against DILI, while the 
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major components in the exosomes which are responsible for the 
regenerative effect were not identified. The confirmation of exosomes 
protective effect should precede the components identification.  Based 
on current knowledge, exosomes comprise vast amounts of different 
proteins, mRNAs and miRNAs. Therefore, further study is needed to 
verify the responsible components which might be related to the 
regenerative effect and to explore its effect in the in vitro system. 
 It should be noted that the exosomes and the contents might exhibit 
batch to batch variation. This variation is inevitable because exosomes 
is a cell based production.  However, to minimize the batch to batch 
variation, each batch of exosomes was subjected for in vivo test in 
MI/R model to confirm its effect before they were used in this study. 
Thus, the development of large scale production of exosomes from 
cultured cells with consistent quality and contents is needed before 
clinical use is considered. 
 The effect of -TP/-T3 in animal model was not explored in this 
study due to the challenges in -TP and -T3 delivery. Owing to their 
high lipophilic properties, -TP and -T3 are usually dissolved in 
ethanol or DMSO. However, the introduction of these two solvents as 
background may have high possibility in causing other complications 
in the CCl4-induced mouse injury model. During the period when this 
study was conducted, the -TP and -T3 formulation to increase its 
bioavailability was ongoing. Therefore, future research should attempt 
to explore the in vivo effect of -TP/-T3 when the formulation is 
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available, since the cellular uptake of both analogs were claimed to be 
totally different from the in vitro findings.   
 It is uncertain if the -T3 possessed higher potency in antioxidant 
properties compared to -TP due to the different cellular uptake. To 
verify this, the cellular content of each analog is required to be 
adjusted to the same amount regardless of the treatment concentration 
so that the protective effect can be compared side by side directly. 
 As an exploratory study to compare the protective effect of different 
T3 analogs and -TP, and the results have proven that only -T3 and 
-TP can protect against DILI. It would be useful to compare the 
potency of -T3 and -TP with the current NAC treatment for DILI in 
the future.  
 Another possible avenue of future work is to explore the post-injury 
treatment of exosomes or -T3 because this will be the ultimate 
approach from the perspective of clinical settings. 
 From the promising preliminary results of the combination therapy, a 
direct extension of this work is to further explore and characterize the 
interactions of exosomes and -T3 against different toxicants-induced 
injuries and their mechanisms of actions in both in vitro and in vivo 
models.  
 It is also important to define whether the effect of the combination 
therapy is additive or synergistic. This work can be extended in the 
future by using the Chou-Talalay method for determining the 
efficiency of this combination therapy.  
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APPENDICES II 
 
Supplementary table 2 Proteomic profile of 3 independently prepared 
exosomes as determined by LC MS/MS and antibody arrays  [187]. 
 
A2M CD81 FAM29A IGFBP3 LYAR PSMB4 SLC7A10 
ABI3BP CD82 FAM3B IGFBP4 LYZ PSMB5 SLC7A5 
ACAA2 CD9 FAM64A IGFBP6 MADH4 PSMB6 SMARCA4 
ACAT2 CDC2L5 FAM71F1 IGFBP7 MAMDC2 PSMB7 SMC1A 
ACLY CDC42 FAP IGHA1 MAP1A PSMB8 SORT1 
ACSL1 CDH13 FASN IGHA2 MAP2K6 PSMB9 SPACA1 
ACTA1 CDIPT FAT IGHG1 MAP3K1 PSMC5 SPARC 
ACTA2 CDK5R2 FAT2 IGHG2 MARCKS PSMD11 SPOCK1 
ACTB CEACAM8 FAT4 IGHG4 MARCKSL1 PSMD14 SPRY4 
ACTG2 CFB FBLN1 IGHM MAT1A PSMD6 SPTAN1 
ACTN1 CFI FBN1 IGJ MBD3 PSMD7 SPTBN1 
ACTN2 CFL1 FBN2 IGKC MCC PTGFRN SPTBN4 
ACTN3 CFL2 FBXW8 IGKV1-5 MCM10 PTK7 SRGN 
ACTN4 CFTR FEN1 IGL@ MDH1 PTPRK SRI 
ACTR1A CHMP2A FER1L3 IGLV4-3 MDH2 PTRF SRPX2 
ACTR2 CHST12 FGA IGSF8 ME1 PTTG1IP ST6GALNAC6 
ACTR3 CITED1 FGB IL10 MECP2 PTX3 STAT1 
ADAM10 CLASP2 FGF16 IL11 MFAP4 PXDN STC1 
ADAM9 CLDN1 FGF18 IL13 MFGE8 PZP STC2 
ADAMTS12 CLEC11A FGF19 IL15RA MFSD2 QPCTL STOM 
AEBP1 CLIC1 FGFRL1 IL17B MIF QSOX1 STOML3 
AFM CLIC6 FGG IL17R MMP1 RAB10 STX12 
AGRN CLPX FLG2 IL19 MMP10 RAB11B STX2 
AHCY CLSTN1 FLJ13197 IL1F9 MMP2 RAB14 SURF4 
AHNAK2 CLTA FLJ22184 IL1RAP MMP3 RAB15 SVEP1 
AHSG CLTC FLJ32784 IL1RAPL1 MOS RAB1A SYT1 
AKR1B1 CLTCL1 FLNA IL1RL2 MPO RAB1B SYT9 
AKR7A2 CLU FLNB IL22RA1 MPZL1 RAB2A TAAR2 
ALB CMIP FLNC IL23A MRC2 RAB33B TAGLN 
ALCAM CNGB1 FLOT1 IL3 MSN RAB35 TALDO1 
ALDH2 COL12A1 FLOT2 IL5 MXRA5 RAB39B TAS2R60 
ALDH3A2 COL14A1 FLT1 IL6ST MYADM RAB5A TCN1 
ALDH6A1 COL18A1 FN1 IL7 MYCBPAP RAB5B TF 
ALDH7A1 COL1A1 FREM3 IL8 MYH14 RAB5C TFG 
ALDH9A1 COL1A2 FST INHBA MYH9 RAB6A TFRC 
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ALDOA COL2A1 FTL INHBB MYL6B RAB7A TGFB1 
ALDOB COL3A1 FUCA2 INSR MYO1C RAB8A TGFB2 
ALDOC COL4A1 GALNT5 IQGAP1 NBL1 RAB8B TGFBI 
ALOX12P2 COL4A2 GANAB ITGA11 NEFH RAC1 TGM2 
ANG COL4A3 GAPDH ITGA2 NEK10 RAC2 TGOLN2 
ANGPTL2 COL5A1 GAPDHS ITGA3 NID1 RAD21 THBS1 
ANPEP COL5A2 GARS ITGA4 NLRP8 RALA THBS2 
ANXA1 COL6A1 GAS6 ITGA5 NME1 RAN THY1 
ANXA11 COL6A2 GDF1 ITGAL NOMO1 RAP1A TIMP1 
ANXA2 COL6A3 GDF11 ITGAV NRAS RAP1B TIMP2 
ANXA2P1 COL7A1 GDF3 ITGB1 NRG2 RAP1B TIMP3 
ANXA3 COMP GDF5 ITGB5 NRLN1 RAP2C TKT 
ANXA4 COPB1 GDF8 ITIH2 NRP1 RARRES1 TLN1 
ANXA5 COPS3 GDF9 ITIH4 NT5E RASA1 TMBIM1 
ANXA6 COPS4 GDI1 ITPR2 NTF5 RASA4 TMED10 
ANXA7 COPS8 GDI2 JUP NUSAP1 RB1CC1 TMED9 
AP1S1 CPS1 GFRA3 KIAA0146 OBFC1 RCOR2 TMEM16B 
APEH CREG1 GLDC KIAA0256 ODZ3 RDH5 TMEM2 
APOA1 CRIPT GLUD1 KIAA0467 OFD1 RFTN1 TMEM47 
APOE CRTAP GNA13 KIAA1881 OPRM1 RGN TMEM51 
APP CSF1 GNAI2 KPNB1 OSM RHOC TNC 
ARF1 CSF2 GNAL KRT1 OTC RMND5A TNFRSF11B 
ARF4 CSF3 GNAS KRT10 OXNAD1 RNF123 TNFRSF12A 
ARF5 CSPG4 GNAT3 KRT13 OXTR RNF40 TNFRSF1A 
ARHGAP18 CST4 GNB1 KRT14 P4HB RPL10A TNFSF18 
ARHGAP23 CTA-221G9.4 GNB2 KRT15 PAICS RPL12 TNFSF5 
ARHGDIA CTBP2 GNB4 KRT16 PAN3 RPL15 TPBG 
ARHGEF1 CTNNA1 GNG12 KRT17 PAPPA RPL18 TPI1 
ARL6IP5 CTNNA2 GNPDA1 KRT18 PARP10 RPL23 TRAP1 
ARMS2 CTNNB1 GOT2 KRT19 PARP16 RPL29 TREM1 
ARPC3 CTNND1 GPC1 KRT2 PARVG RPL35A TREML2P 
ARPC4 CTSG GPC5 KRT27 PC RPLP0 TRIM40 
ARPC5 CXCL16 GPI KRT28 PCOLCE RPS10 TRIM41 
ASH1L CXCL2 GPR112 KRT3 PDCD6 RPS16 TSN 
ASL CXorf39 GREM1 KRT4 PDCD6IP RPS18 TSNAX 
ATP1A1 CYBRD1 GRM2 KRT5 PDGFA RPS2 TSPAN14 
ATP1B3 DBF4B GRM3 KRT6A PDGFC RPS24 TSPAN4 
ATP2B1 DCD GRM7 KRT6B PDGFRB RPS27A TSPAN6 
ATP2B4 DCHS2 GSN KRT6C PDIA3 RPS3 TSPAN9 
ATP5A1 DCLK2 GSTM1 KRT7 PEBP1 RPS4X TSTA3 
ATP5B DCN GSTM2 KRT72 PFAS RPS5 TTLL3 
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ATP8B3 DCTN1 GSTM5 KRT73 PFKFB3 RPSA TTN 
ATRN DECR1 GSTO1 KRT74 PFN1 RRAS2 TTYH3 
ATXN1 DEFA1 GSTP1 KRT76 PFN2 RTN4 TUBA1A 
AXL DIP2B GTPBP2 KRT77 PGAM2 RUVBL1 TUBA1B 
BASP1 DIRAS2 GYLTL1B KRT78 PGD S100A11 TUBA1C 
BDNF DKFZp686D0972 GZMA KRT79 PGK1 S100A13 TUBB 
BGN DKK1 H2AFV KRT8 PGLYRP2 S100A8 TUBB2A 
BHMT2 DKK3 H2AFX KRT80 PIGR S100P TUBB2C 
BRMS1 DMBT1 HBB KRT84 PIP SAA4 TUBB3 
BSG DNASE1L1 HBE1 KRT9 PKM2 SASS6 TUBB6 
C11orf59 DNPEP HDAC5 LACRT PLAB SCAMP3 UBA52 
C1orf78 DPYS HERC5 LAMA4 PLAU SCGB2A1 UBB 
C1R DPYSL2 HGF LAMB1 PLEC1 SCYE1 UBE1 
C1S DSP HGFR LAMC1 PLEKHG3 SDC1 UBE2N 
C20orf114 DULLARD HISPPD2A LAMP1 PLOD1 SDC2 UGP2 
C3 ECM1 HIST1H2AE LAMP2 PLOD2 SDC4 UNC13B 
C5orf24 ED1 HIST1H2BA LAP3 PLOD3 SDCBP UNC45A 
C9orf19 EDG2 HIST1H2BL LCN1 PLP2 SEC14L4 VAMP3 
C9orf91 EDIL3 HIST1H4H LCN2 PLSCR3 SEMA5A VANGL1 
CACNA2D1 EEA1 HIST2H2BE LDHA PLTP Sep-02 VASN 
CACNA2D4 EEF1A1 HLAA LDHAL6B PLUNC Sep-07 VAT1 
CALR EEF1G HMGCS2 LDHB PNO1 SERINC5 VCAN 
CAND1 EEF2 HNRNPA1 LEPRE1 PODN SERPINA1 VCL 
CAP1 EFEMP2 HP LGALS1 POLN SERPINB3 VCP 
CAPNS1 EHD1 HPX LGALS3 POSTN SERPINE1 VEGFC 
CAPZA1 EHD2 HRSP12 LGALS3BP POTE2 SERPINE2 VIL1 
CASP14 EHD4 HSP90AA1 LGALS8 PPIA SERPINF1 VIL2 
CAT EIF4A1 HSP90AB1 LGR6 PPIB SFN VIM 
CAV1 EMILIN1 HSP90B1 LIF PPME1 SFRP1 VTI1A 
CCDC129 ENG HSPA1A LMNA PPP1CC SFRP4 VTN 
CCDC64B ENO1 HSPA1L LOC124220 PRDM16 SHANK3 WDR49 
CCL2 ENO2 HSPA5 LOC283523 PRDX1 SLAIN1 WDR52 
CCL20 ENO3 HSPA6 LOC284297 PRDX6 SLC16A1 WNT5A 
CCL28 ENTPD4 HSPA8 LOC388344 PRNP SLC16A3 YBX1 
CCL7 ENTPD4;LOXL2 HSPB1 LOC389827 PRR4 SLC1A4 YWHAB 
CCR4 EPB41L3 HSPD1 LOC442497 PRSS23 SLC1A5 YWHAE 
CCR5 EPHA2 HSPG2 LOC653269 PSMA1 SLC22A2 YWHAG 
CCT5 EPO HTRA1 LOC727942 PSMA2 SLC25A10 YWHAQ 
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CCT6A ESM1 HYI LOC728320 PSMA3 SLC25A13 YWHAZ 
CD109 ETFB ICAM1 LOC728378 PSMA4 SLC2A1 ZBTB4 
CD151 F2R ICAM5 LOC730013 PSMA5 SLC2A3 ZNF134 
CD248 F3 IDH3B LRP1 PSMA6 SLC38A2 ZNF503 
CD276 F8 IFITM2 LRP6 PSMA7 SLC38A3 ZNF614 
CD44 FADD IFNG LRRFIP2 PSMB1 SLC39A14 
 
CD47 FAH IFRD1 LTBP1 PSMB10 SLC3A2 
 
CD59 FAM108A1 IFT140 LTBP2 PSMB2 SLC44A1 
 
CD63 FAM129B IGF2R LTF PSMB3 SLC44A2 
   
Regular font: identified by LC MS/MS. 
Underline: identified by antibody arrays. 
Bold and Underline: identified by both LC MS/MS and antibody arrays. 
Bold: identified by LC MS/MS and was found to be present in at least 50% of  
           exosomes characterized. 
 
 
